image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
be493fa4d39b0cf55486eaffcc09020162867fd938db2c2433163dc1d1d25a3a.png | simple | <table><tr><td>Partition</td><td>Resolution<sup>1</sup></td><td>TE MAFFT<sup>2</sup></td><td>TE BAli-Phy<sup>2</sup></td><td>Protein coding</td></tr><tr><td>rRNA MAFFT</td><td>95%</td><td>0.287</td><td>0.264</td><td>0.309</td></tr><tr><td>rRNA BAli-Phy</td><td>95%</td><td>0.272</td><td>0.221</td><td>0.261</td></tr><tr><td>CAD</td><td>91%</td><td>0.339</td><td>0.329</td><td>0.207</td></tr><tr><td>EFF1</td><td>79%</td><td>0.434</td><td>0.440</td><td>0.404</td></tr><tr><td>EFF2</td><td>67%</td><td>0.403</td><td>0.416</td><td>0.419</td></tr><tr><td>POL</td><td>77%</td><td>0.438</td><td>0.458</td><td>0.415</td></tr><tr><td>CO1</td><td>74%</td><td>0.384</td><td>0.381</td><td>0.358</td></tr><tr><td>Morphology</td><td>91%</td><td>0.292</td><td>0.298</td><td>0.362</td></tr></table> |
6320f4d036f8f47af1e345e1d356ac57fd83a0d3fd235723a6bf30933f2cdad7.png | simple | <table><tr><td>Variable</td><td>Carotid Score</td><td>m-IMT</td><td>Left Ventricular Mass</td></tr><tr><td>Age</td><td>r = 0.53p < 0.01</td><td>r = 0.46p < 0.01</td><td>-</td></tr><tr><td>Weight</td><td>-</td><td>-</td><td>r = 0.53p < 0.01</td></tr><tr><td>Height</td><td>-</td><td>-</td><td>r = 0.38p < 0.05</td></tr><tr><td>Body Mass Index</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Waist Circumference</td><td>-</td><td>-</td><td>r = 0.57p < 0.001</td></tr><tr><td>Systolic BP</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Diastolic BP</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Pulse Pressure</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Heart Rate</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Total Cholesterol</td><td>-</td><td>-</td><td>-</td></tr><tr><td>HDL Cholesterol</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Total/HDL Ratio</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Triglycerides</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Glucose</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Insulin</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Creatinine</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Uric acid</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Progetto CuoreScore</td><td>r = 0.55p < 0.001</td><td>r = 0.36p < 0.05</td><td>-</td></tr><tr><td>Progetto CuoreScore – Logarithm</td><td>r = 0.54p < 0.01</td><td>r = 0.43p < 0.05</td><td>-</td></tr></table> |
d74b60f0bc226aea809cd2a27ea3aa266c940c3d4d3952c424378643e19de0ae.png | simple | <table><tr><td></td><td>MCF-7</td><td>MDA-MB-231</td></tr><tr><td>SSTR1</td><td>++</td><td>+++</td></tr><tr><td>SSTR2</td><td>+++</td><td>++</td></tr><tr><td>SSTR3</td><td>+</td><td>+</td></tr><tr><td>SSTR4</td><td>++++</td><td>++++</td></tr><tr><td>SSTR5</td><td>+</td><td>+</td></tr></table> |
1dc7eec4c7b7a21fca810981df04035219392e4e8f1689a4673f904646c139e7.png | simple | <table><tr><td>Characteristic</td><td>Coefficient (95% CI)</td><td><i>p</i>-value</td></tr><tr><td>Treatment regimen</td><td></td><td>0.04</td></tr><tr><td> Prophylaxis</td><td>10.0 (0.7, 19.3)</td><td></td></tr><tr><td> On-demand</td><td>reference</td><td></td></tr><tr><td>Chronic pain<sup>b</sup></td><td></td><td>0.03</td></tr><tr><td> Moderate to severe</td><td>−10.0 (−19.2, −0.8)</td><td></td></tr><tr><td> None to mild</td><td>reference</td><td></td></tr></table> |
462ddc722405bc42bef7faabfb25dbce4341d95dc3cac7f2402363eb32a38fa6.png | simple | <table><tr><td>Subgroups</td><td>HR</td><td>95% CI</td><td><i>P</i> Value</td></tr><tr><td>Patients with diabetes mellitus</td><td>0.36</td><td>0.14 to 0.90</td><td>0.03</td></tr><tr><td>Patients without diabetes mellitus</td><td>0.74</td><td>0.41 to 1.33</td><td>0.32</td></tr><tr><td>Patients with hypertension</td><td>0.57</td><td>0.36 to 0.92</td><td>0.02</td></tr><tr><td>Patients with hyperlipidemia</td><td>0.93</td><td>0.38 to 2.27</td><td>0.89</td></tr><tr><td>Patients with normal lipids</td><td>0.47</td><td>0.26 to 0.83</td><td>0.009</td></tr><tr><td>Patients with prior myocardial infarction</td><td>1.36</td><td>0.30 to 6.1</td><td>0.70</td></tr><tr><td>Patients with no prior myocardial infarction</td><td>0.57</td><td>0.35 to 0.94</td><td>0.02</td></tr><tr><td>Patients with major cardiac adverse events</td><td>0.30</td><td>0.08 to 1.13</td><td>0.07</td></tr><tr><td>Patients with no major cardiac adverse events</td><td>0.59</td><td>0.36 to 0.97</td><td>0.04</td></tr></table> |
edc357e374654751ae0189a7f638a1c483bd7b662c3d1135146f6bc4adbef848.png | simple | <table><tr><td></td><td><i>baseline n (%)</i></td><td><i>six months n (%)</i></td></tr><tr><td>Nightly pain</td><td>75 (34.7%)</td><td>68 (31.5%)</td></tr><tr><td></td><td></td><td>(38 (50.7%) persistent)<sup>b</sup></td></tr><tr><td>Unbearable pain</td><td>29 (13.4%)</td><td>34 (15.7%)</td></tr><tr><td></td><td></td><td>(17 (58.6%) persistent)</td></tr><tr><td>Pain when changing position</td><td>88 (40.7%)</td><td>83 (38.4%)</td></tr><tr><td></td><td></td><td>(57 (64.8%) persistent)</td></tr><tr><td>Pain when walking</td><td>45 (20.8%)</td><td>44 (20.4%)</td></tr><tr><td></td><td></td><td>(23 (51.1%) persistent)</td></tr><tr><td>Pain when standing</td><td>49 (22.7%)</td><td>41 (19.0%)</td></tr><tr><td></td><td></td><td>(17 (34.7%) persistent)</td></tr><tr><td>Constant pain</td><td>50 (23.1%)</td><td>47 (21.8%)</td></tr><tr><td></td><td></td><td>(33 (66.0%) persistent)</td></tr><tr><td>Pain when stair climbing</td><td>7 (3.2%)</td><td>3 (1.4%)</td></tr><tr><td></td><td></td><td>(1 (14.3%) persistent)</td></tr><tr><td>Pain when sitting</td><td>89 (41.2%)</td><td>66 (30.6%)</td></tr><tr><td></td><td></td><td>(44 (49.4%) persistent)</td></tr></table> |
fa3b7b69c2adc38cf88134c231bff4b1aa6d5f35e560baae837ac9a1123a1696.png | simple | <table><tr><td>Assays<sup><i>b</i></sup></td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>Accuracy (%)</td><td>LR+<sup><i>c</i></sup></td><td>LR−<sup><i>d</i></sup></td><td>DOR<sup><i>e</i></sup></td><td>ROC analysis, AUC (95% CI)</td></tr><tr><td>WB PCR<sup><i>f</i></sup> (95% CI)</td><td>73 (54–86)</td><td>92 (76–98)</td><td>82.7</td><td>9.5</td><td>0.3</td><td>32.7</td><td></td></tr><tr><td>Serum PCR (95% CI)</td><td>65 (46–81)</td><td>79 (60–91)</td><td>72.0</td><td>3.1</td><td>0.4</td><td>7.3</td><td></td></tr><tr><td>GM (95% CI)</td><td>68 (47–84)</td><td>80 (61–91)</td><td>74.5</td><td>3.4</td><td>0.4</td><td>8.5</td><td>0.77 (0.62–0.91)</td></tr><tr><td>BDG (95% CI)</td><td>46 (27–65)</td><td>100 (86–100)</td><td>74.5</td><td>>455</td><td>0.6</td><td>>827.3</td><td>0.82 (0.70–0.95)</td></tr><tr><td>Serum/WB PCR</td><td>91/33</td><td>65/100</td><td>77/68</td><td>2.6/>330</td><td>0.1/0.7</td><td>18.6/>495</td><td>0.84 (0.72–0.96)</td></tr><tr><td>BDG/WB PCR</td><td>86/24</td><td>91/100</td><td>89/64</td><td>9.6/>240</td><td>0.2/0.8</td><td>48/>300</td><td>0.90 (0.79–1.00)</td></tr><tr><td>GM/WB PCR</td><td>100/33</td><td>78/96</td><td>89/66</td><td>4.5/8.3</td><td><0.001/0.7</td><td>>4500/11.8</td><td>0.91 (0.81–1.00)</td></tr><tr><td>BDG/serum PCR</td><td>76/33</td><td>74/100</td><td>75/68</td><td>2.9/>330</td><td>0.3/0.7</td><td>9.7/>471</td><td>0.79 (0.66–0.93)</td></tr><tr><td>GM/serum PCR</td><td>90/43</td><td>61/96</td><td>75/70</td><td>2.3/10.8</td><td>0.2/0.6</td><td>11.5/18</td><td>0.82 (0.70–0.95)</td></tr><tr><td>GM/BDG</td><td>81/38</td><td>83/100</td><td>82/70</td><td>4.8/>380</td><td>0.2/0.6</td><td>24/>613</td><td>0.85 (0.73–0.97)</td></tr><tr><td>WB PCR/GM/BDG</td><td>100/67/14</td><td>78/96/100</td><td>89/82/59</td><td>4.5/16.8/>140</td><td><0.001/0.3/0.9</td><td>>5000/57/>156</td><td>0.95 (0.88–1.00)</td></tr><tr><td>Serum PCR/GM/BDG</td><td>100/48/33</td><td>61/96/100</td><td>80/73/68</td><td>2.6/12/>330</td><td><0.002/0.5/0.7</td><td>>1300/24/>471</td><td>0.88 (0.79–0.98)</td></tr><tr><td>WB/serum PCR/BDG</td><td>90/71/10</td><td>65/100/100</td><td>77/86/57</td><td>2.6/>710/>100</td><td>0.2/0.3/0.9</td><td>13/>2367/>111</td><td>0.90 (0.81–1.00)</td></tr><tr><td>WB/serum PCR/GM</td><td>100/81/14</td><td>57/91/100</td><td>77/86/59</td><td>2.3/9/>140</td><td><0.002/0.2/0.9</td><td>>187/45/>156</td><td>0.92 (0.84–1.00)</td></tr><tr><td>All four assays</td><td>100/91/44/10</td><td>57/91/100/100</td><td>77/91/73/57</td><td>2.3/10.4/>429/>950</td><td><0.001/0.1/0.6/0.9</td><td>>2300/104/>751/>1044</td><td>0.95 (0.90–1.00)</td></tr></table> |
a60470b8b17ce8aec5df4700cb9faa82781f7efcca03746635352fb555174cfb.png | simple | <table><tr><td></td><td>NSR (<i>n =</i> 361)</td><td>AF (<i>n =</i> 81)</td><td><i>p</i></td></tr><tr><td>Before surgery</td><td></td><td></td><td></td></tr><tr><td> LV end diastolic dimension (mm)</td><td>56.6 ± 10.8</td><td>55.0 ± 10.9</td><td>0.375</td></tr><tr><td> LV end systolic dimension (mm)</td><td>38.4 ± 9.2</td><td>38.7 ± 9.9</td><td>0.863</td></tr><tr><td> LV ejection fraction (%)</td><td>62.7 ± 10.0</td><td>58.9 ± 14.1</td><td>0.026</td></tr><tr><td> LA antero-posterior dimension (AP) (mm)</td><td>50.7 ± 8.7</td><td>53.1 ± 6.9</td><td>0.080</td></tr><tr><td> LA medio-lateral dimension (ML) (mm)</td><td>56.2 ± 10.6</td><td>58.6 ± 9.9</td><td>0.339</td></tr><tr><td> LA supero-inferior dimension (SI) (mm)</td><td>62.4 ± 9.7</td><td>60.4 ± 9.1</td><td>0.372</td></tr><tr><td> LA volume index (ml/m<sup>2</sup>)<sup>a</sup></td><td>58.4 ± 24.9</td><td>62.9 ± 22.8</td><td>0.399</td></tr><tr><td> TR grade</td><td>0.4 ± 0.8</td><td>1.2 ± 1.1</td><td>0.005</td></tr><tr><td> Estimated PAP</td><td>39.2 ± 17.5</td><td>44.5 ± 18.4</td><td>0.252</td></tr><tr><td>After surgery</td><td></td><td></td><td></td></tr><tr><td> LV end diastolic dimension (mm)</td><td>48.9 ± 5.3</td><td>50.1 ± 8.9</td><td>0.126</td></tr><tr><td> LV end systolic dimension (mm)</td><td>33.8 ± 5.8</td><td>35.9 ± 10.8</td><td>0.015</td></tr><tr><td> LV ejection fraction (%)</td><td>60.9 ± 9.5</td><td>57.2 ± 13.8</td><td>0.006</td></tr><tr><td> LA AP dimension (mm)</td><td>42.9 ± 6.0</td><td>50.7 ± 8.1</td><td>< .001</td></tr><tr><td> LA ML dimension (mm)</td><td>50.3 ± 6.8</td><td>56.3 ± 7.5</td><td>< .001</td></tr><tr><td> LA SI dimension (mm)</td><td>57.3 ± 27.5</td><td>61.8 ± 8.2</td><td>0.172</td></tr><tr><td> LA AP change (mm)</td><td>7.7 ± 8.4</td><td>4.1 ± 7.9</td><td>0.011</td></tr><tr><td> LA ML change (mm)</td><td>6.7 ± 10.4</td><td>3.4 ± 10.1</td><td>0.197</td></tr><tr><td> LA SI change (mm)</td><td>7.4 ± 9.0</td><td>1.3 ± 8.3</td><td>0.005</td></tr><tr><td> LA volume index (ml/m<sup>2</sup>)</td><td>37.9 ± 12.6</td><td>52.1 ± 15.6</td><td>< .001</td></tr><tr><td> LA volume change (ml/m<sup>2</sup>)</td><td>20.5 ± 21.3</td><td>10.8 ± 23.4</td><td>0.041</td></tr><tr><td> LA volume change %</td><td>28.1 ± 27.9</td><td>9.5 ± 36.8</td><td>< .001</td></tr><tr><td> MDPG of the MV (mmHg)</td><td>3.5 ± 1.4</td><td>3.9 ± 1.5</td><td>0.023</td></tr><tr><td> Residual mitral regurgitation</td><td></td><td></td><td>0.337</td></tr><tr><td>No</td><td>352 (97.5%)</td><td>77 (95.1%)</td><td></td></tr><tr><td>Trivial</td><td>8 (2.2%)</td><td>3 (3.7%)</td><td></td></tr><tr><td>More than grade I</td><td>1 (0.3%)</td><td>1 (1.2%)</td><td></td></tr><tr><td> TR grade</td><td>0.3 ± 0.6</td><td>1.0 ± 1.0</td><td>< 0.001</td></tr><tr><td> Estimated PAP</td><td>26.4 ± 6.6</td><td>29.8 ± 7.1</td><td>0.001</td></tr><tr><td> TAP or TVR</td><td>33 (7.5%)</td><td>6 (1.4%)</td><td>0.828</td></tr></table> |
7c784c013f61449d0ef01178c253511a64ed46e3d54ac321aa2ac19b84c16dd7.png | simple | <table><tr><td> </td><td> </td></tr><tr><td>•</td><td>‘I would prefer to see the same consultant in hospital, as I trust her already and would find it hard to build the same level of trust with someone else’</td></tr><tr><td>•</td><td>‘Continuity of care- New consultant may not read all information or interpret it differently’</td></tr><tr><td>•</td><td>‘A relationship of trust with your own consultant takes time to build and could never be done with a stranger that you meet now and again’</td></tr><tr><td>•</td><td>‘I’d prefer the above mainly for comfort and familiarity. I’ve shared my condition and stories enough times; having to repeat everything is pointless and counterproductive. It feels like an exercise in futility’</td></tr><tr><td>•</td><td>‘Continuity of care. I feel it would be best for me to have my care managed by someone who is familiar with me and can compare my symptoms with when I am well’</td></tr><tr><td>•</td><td>‘Over the past 5 years, I have had annual review as an outpatient and have seen a few different psychiatrists each time. I would prefer to be seen by one psychiatrist and also if admitted to hospital to see the same one’</td></tr><tr><td>•</td><td>‘Seeing the same doctor means you do not have to repeat your illness every time as this can be upsetting’</td></tr><tr><td>•</td><td>‘On one hand having the same consultant might give a sense of security. On the other hand, a different consultant having slightly different experiences, may also be a good thing-My personal view is that I would rather choose to have the same consultant’</td></tr></table> |
456e75af606352144ff156724151c0ca165298a96b922b4c117f0972cc5ea284.png | simple | <table><tr><td>Medium</td><td></td><td>Score</td></tr><tr><td>Ham's F-12</td><td>+10% FCS</td><td>180</td></tr><tr><td>DMEM/Ham's F-12 (1:1)</td><td>+10% FCS</td><td>170</td></tr><tr><td>Medium199</td><td>+10% FCS</td><td>165</td></tr><tr><td>DMEM</td><td>+10% FCS</td><td>165</td></tr><tr><td>McCoy's 5A</td><td>+10% FCS</td><td>140</td></tr></table> |
aecc24deaeaf216080a2bc52f64adcd2ee147818a91ce7e6e7262b974d386559.png | simple | <table><tr><td>Author, Year, Citation</td><td>Sample size*</td><td>Respondents who reported the PtDA was balanced.n (%)</td><td>Did the PtDA include side-by-side display of evidence?</td><td>Did the PtDA include any side-by-side display?</td></tr><tr><td>Mathieu, Barratt et al., 2010 [14]</td><td>117</td><td>66 (57%)</td><td>no</td><td>no</td></tr><tr><td>Smith, Trevena et al., 2010 [15]</td><td>334</td><td>160 (48%)</td><td>no</td><td>no</td></tr><tr><td>Griffith, Fichter et al., 2008 [6]</td><td>106</td><td>17 (16%)</td><td>unclear</td><td>unclear</td></tr><tr><td>Spunt, Deyo et al., 1996 [16]</td><td>239</td><td>133 (56%)</td><td>unclear</td><td>unclear</td></tr><tr><td>Anderson, Carter et al., 2011 [17]</td><td>19</td><td>17 (89%)</td><td>no</td><td>yes</td></tr><tr><td>Watson, Hewitson et al., 2006 [18]</td><td>468</td><td>439 (94%)</td><td>no</td><td>yes</td></tr><tr><td>Drake, Engler-Todd et al., 1999 [19]</td><td>38</td><td>27 (71%)</td><td>yes</td><td>yes</td></tr><tr><td>Lalonde, O’Connor et al., 2004 [20]</td><td>16</td><td>13 (80%)</td><td>yes</td><td>yes</td></tr><tr><td>van Tol-Geerdink, Stalmeier et al., 2006 [21]</td><td>150</td><td>142 (95%)</td><td>yes</td><td>yes</td></tr><tr><td>van Tol-Geerdink, Leer et al., submitted [22]</td><td>153</td><td>147 (96%)</td><td>yes</td><td>yes</td></tr></table> |
088596795b3884bc7ea46a0611cef63c721996e7a98bb2f7bf2332c493141860.png | simple | <table><tr><td>Position of the tapes</td><td>at 3 months after surgery</td><td>at 6 months after surgery</td><td>at one year after surgery</td></tr><tr><td>Proximal third of the urethra</td><td>3,92 %</td><td>9,81 %</td><td>9,81 %</td></tr><tr><td>The middle third of the urethra</td><td>88,23 %</td><td>82,35 %</td><td>82,35 %</td></tr><tr><td>Distal third</td><td>7,84 %</td><td>7,84 %</td><td>7,84 %</td></tr></table> |
cc913866ad24154fd169ea0f55d68ee66a6f287ff8b2fc33c99d37fb1c2ea536.png | complex | <table><tr><td rowspan="2">Semester</td><td colspan="2">Nominees</td><td colspan="2">Non-nominees</td></tr><tr><td>Weekday</td><td>Weekend</td><td>Weekday</td><td>Weekend</td></tr><tr><td>Semester 1</td><td>97</td><td>63</td><td>28</td><td>8</td></tr><tr><td>Semester 2</td><td>303</td><td>144</td><td>42</td><td>13</td></tr></table> |
dc1c2e2697d8a986b783526df1d970359d1f2c23e94a93dc09f1ea1da74fcec7.png | complex | <table><tr><td>Variables</td><td colspan="3">CSS</td><td colspan="3">OS</td></tr><tr><td></td><td>HR</td><td>95%CI</td><td><i>p</i>-Value</td><td>HR</td><td>95%CI</td><td><i>p</i>-Value</td></tr><tr><td>Age (continuous variable)</td><td>1.037</td><td>1.027–1.048</td><td><0.001</td><td>1.041</td><td>1.032–1.049</td><td><0.001</td></tr><tr><td colspan="7">Race</td></tr><tr><td>Non-Hispanic White</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Non-Hispanic Black</td><td>0.478</td><td>0.245–0.932</td><td>0.030</td><td>0.698</td><td>0.444–1.098</td><td>0.119</td></tr><tr><td>Hispanic (all Races)</td><td>0.881</td><td>0.581–1.336</td><td>0.550</td><td>0.898</td><td>0.643–1.255</td><td>0.529</td></tr><tr><td>Other</td><td>0.312</td><td>0.100–0.977</td><td>0.046</td><td>0.403</td><td>0.179–0.904</td><td>0.027</td></tr><tr><td colspan="7">Tumor grade</td></tr><tr><td>Well differentiated</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Moderately differentiated</td><td>0.937</td><td>0.646–1.358</td><td>0.730</td><td>0.972</td><td>0.719–1.314</td><td>0.853</td></tr><tr><td>Poorly/undifferentiated</td><td>0.852</td><td>0.570–1.272</td><td>0.433</td><td>0.879</td><td>0.635–1.217</td><td>0.436</td></tr><tr><td>Tumor size (continuous variable)</td><td>1.013</td><td>1.009–1.018</td><td><0.001</td><td>1.012</td><td>1.008–1.016</td><td><0.001</td></tr><tr><td colspan="7">Number of PLNs (<i>n</i>)</td></tr><tr><td>1</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>2</td><td>1.408</td><td>1.007–1.969</td><td>0.046</td><td>1.156</td><td>0.879–1.521</td><td>0.3</td></tr><tr><td>≥3</td><td>2.367</td><td>1.753–3.197</td><td> < 0.001</td><td>2.208</td><td>1.744–2.796</td><td><0.001</td></tr><tr><td colspan="7">Number of RLNs (<i>n</i>)</td></tr><tr><td>7–10</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>1–6</td><td>1.588</td><td>1.113–2.266</td><td>0.011</td><td>1.335</td><td>1.008–1.767</td><td>0.044</td></tr><tr><td>11–16</td><td>0.782</td><td>0.530–1.153</td><td>0.215</td><td>0.712</td><td>0.527–0.961</td><td>0.027</td></tr><tr><td>17–45</td><td>0.962</td><td>0.653–1.416</td><td>0.844</td><td>0.817</td><td>0.603–1.107</td><td>0.192</td></tr><tr><td colspan="7">Adjuvant radiotherapy</td></tr><tr><td>No</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>0.806</td><td>0.612–1.062</td><td>0.126</td><td>0.721</td><td>0.580–0.895</td><td>0.003</td></tr><tr><td colspan="7">Chemotherapy</td></tr><tr><td>No/unknown</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>0.917</td><td>0.688–1.222</td><td>0.556</td><td>0.744</td><td>0.584–0.947</td><td>0.016</td></tr></table> |
9a89d15fa2119ac6b27224eeb6e9483c75bdb255ec1613b4f62c32a8e56e09bb.png | simple | <table><tr><td></td><td>6 months</td><td></td><td></td><td>12 months</td><td></td><td></td></tr><tr><td>Characteristics</td><td>n/N (%)</td><td>RR</td><td>95%CI</td><td>n/N (%)</td><td>RR</td><td>95%CI</td></tr><tr><td>Minority</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>593/627 (94.6%)</td><td></td><td></td><td>481/513 (93.8%)</td><td></td><td></td></tr><tr><td>Yes</td><td>546/662 (82.5%)</td><td>0.87</td><td>0.84-0.91</td><td>402/487 (82.5%)</td><td>0.88</td><td>0.84-0.92</td></tr><tr><td>Family composition</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>One child</td><td>533/589 (90.5%)</td><td></td><td></td><td>436/478 (91.2%)</td><td></td><td></td></tr><tr><td>Two children</td><td>474/532 (89.1%)</td><td>0.98</td><td>0.95-1.02</td><td>351/400 (87.8%)</td><td>0.96</td><td>0.92-1.01</td></tr><tr><td>More than 3 children</td><td>138/174 (79.3%)</td><td>0.88</td><td>0.81-0.95</td><td>102/128 (79.7%)</td><td>0.87</td><td>0.80-0.96</td></tr><tr><td>Child’s health insurance</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Public</td><td>733/793 (92.4%)</td><td></td><td></td><td>583/645 (90.4%)</td><td></td><td></td></tr><tr><td>Other</td><td>397/486 (81.7%)</td><td>0.88</td><td>0.84 - 0.93</td><td>295/348 (84.8%)</td><td>0.94</td><td>0.89-0.99</td></tr><tr><td>Mother’s age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤20</td><td>43/89 (48.3%)</td><td></td><td></td><td>26/54 (48.1%)</td><td></td><td></td></tr><tr><td>21-30</td><td>552/613 (90.0%)</td><td>1.86</td><td>1.50-2.31</td><td>436/495 (88.1%)</td><td>1.83</td><td>1.38-2.42</td></tr><tr><td>31-40</td><td>500/541 (92.4%)</td><td>1.91</td><td>1.54-2.37</td><td>385 / 415 (92.8%)</td><td>1.93</td><td>1.46-2.54</td></tr><tr><td>≥41</td><td>50/52 (96.2%)</td><td>1.99</td><td>1.59-2.48</td><td>42 / 42 (100.0%)</td><td>NA</td><td>NA-NA</td></tr><tr><td>Father’s age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤20</td><td>23/46 (50.0%)</td><td></td><td></td><td>11/26 (42.3%)</td><td></td><td></td></tr><tr><td>21-30</td><td>284/350 (81.1%)</td><td>1.62</td><td>1.21-2.18</td><td>231/279 (82.8%)</td><td>1.96</td><td>1.25-3.08</td></tr><tr><td>31-40</td><td>626/661 (94.7%)</td><td>1.89</td><td>1.42-2.53</td><td>472/515 (91.7%)</td><td>2.17</td><td>1.38-3.40</td></tr><tr><td>≥41</td><td>205/229 (89.5%)</td><td>1.79</td><td>1.34-2.40</td><td>170/181 (93.9%)</td><td>2.22</td><td>1.41-3.48</td></tr><tr><td>Mother’s education</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Illiterate</td><td>57/111 (51.4%)</td><td></td><td></td><td>28/71 (39.4%)</td><td></td><td></td></tr><tr><td>< high school</td><td>180/225 (80.0%)</td><td>1.56</td><td>1.29-1.89</td><td>132/163 (81.0%)</td><td>2.05</td><td>1.52-2.77</td></tr><tr><td>High school</td><td>538/567 (94.9%)</td><td>1.85</td><td>1.54-2.22</td><td>425/450 (94.4%)</td><td>2.39</td><td>1.79-3.20</td></tr><tr><td>>high school</td><td>355/377 (94.2%)</td><td>1.83</td><td>1.53-2.20</td><td>29/307 (94.5%)</td><td>2.40</td><td>1.79-3.20</td></tr><tr><td>Father’s education</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Illiterate</td><td>49/102 (48.0%)</td><td></td><td></td><td>29/66 (43.9%)</td><td></td><td></td></tr><tr><td>< high school</td><td>180/219 (82.2%)</td><td>1.71</td><td>1.39-2.11</td><td>119/154 (77.3%)</td><td>1.76</td><td>1.32-2.34</td></tr><tr><td>High school</td><td>609/646 (94.3%)</td><td>1.96</td><td>1.60-2.40</td><td>499/529 (94.3%)</td><td>2.15</td><td>1.63-2.82</td></tr><tr><td>>high school</td><td>276/292 (94.5%)</td><td>1.97</td><td>1.60-2.41</td><td>214/228 (93.9%)</td><td>2.14</td><td>1.62-2.81</td></tr><tr><td>Mother’s occupation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Unemployed</td><td>422/519 (81.3%)</td><td></td><td></td><td>332/406 (81.8%)</td><td></td><td></td></tr><tr><td>Blue collar Worker</td><td>11/15 (73.3%)</td><td>0.90</td><td>0.66-1.23</td><td>8/11 (72.7%)</td><td>0.89</td><td>0.62-1.28</td></tr><tr><td>Public sector employee</td><td>98/99 (99.0%)</td><td>1.22</td><td>1.16-1.27</td><td>84/84 (100.0%)</td><td>NA</td><td>NA-NA</td></tr><tr><td>Private sector employee</td><td>297/311 (95.5%)</td><td>1.17</td><td>1.12-1.23</td><td>240/245 (98.0%)</td><td>1.20</td><td>1.14-1.26</td></tr><tr><td>Father’s occupation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Unemployed</td><td>167/207 (80.7%)</td><td></td><td></td><td>118/160 (73.8%)</td><td></td><td></td></tr><tr><td>Worker</td><td>204/266 (76.7%)</td><td>0.95</td><td>0.87-1.04</td><td>163/201 (81.1%)</td><td>1.10</td><td>0.98-1.23</td></tr><tr><td>Public sector employee</td><td>114/125 (91.2%)</td><td>1.13</td><td>1.04-1.23</td><td>99/99 (100.0%)</td><td>NA</td><td>NA-NA</td></tr><tr><td>Private sector employee</td><td>426/436 (97.7%)</td><td>1.21</td><td>1.13-1.30</td><td>342/359 (95.3%)</td><td>1.29</td><td>1.17-1.42</td></tr></table> |
76c5278e63ed469a2097cb31c4ea34308026d985dfe1c7f2829e79b019087f87.png | complex | <table><tr><td></td><td></td><td colspan="3">Age group</td><td></td></tr><tr><td>Baseline characteristic</td><td></td><td>Overall cohort (<i>n</i>=41,088)</td><td>>50 years (<i>n</i>=2591)</td><td>15 to 50 years (<i>n</i>=38,497)</td><td><i>p</i>-value (>50 <i>vs</i> 15 to 50 years)</td></tr><tr><td>Age (years)</td><td>Median (IQR)</td><td>34 (29, 40)</td><td>53 (51, 57)</td><td>33 (29, 38)</td><td>N/A</td></tr><tr><td>Sex <i>n</i> (%)</td><td>Female</td><td>19,891 (48.4)</td><td>1225 (47.3)</td><td>18,666 (48.5)</td><td>0.24*</td></tr><tr><td></td><td>Male</td><td>21,184 (51.6)</td><td>1365 (52.7)</td><td>19,819 (51.5)</td><td></td></tr><tr><td></td><td>Not available</td><td>13 (0.0)</td><td>1 (0.0)</td><td>12 (0.0)</td><td></td></tr><tr><td>WHO Stage <i>n</i> (%)</td><td>1</td><td>3722 (9.1)</td><td>180 (7.0)</td><td>3542 (9.2)</td><td><0.01*</td></tr><tr><td></td><td>2</td><td>3951 (9.6)</td><td>277 (10.7)</td><td>3674 (9.5)</td><td></td></tr><tr><td></td><td>3</td><td>20,549 (50.0)</td><td>1435 (55.6)</td><td>19,114 (49.7)</td><td></td></tr><tr><td></td><td>4</td><td>12,057 (29.3)</td><td>635 (24.6)</td><td>11,422 (29.7)</td><td></td></tr><tr><td></td><td>Not available</td><td>809 (2.0)</td><td>64 (2.5)</td><td>745 (1.9)</td><td></td></tr><tr><td>Baseline CD4 <i>n</i> (%)</td><td><200</td><td>16,038 (39.0)</td><td>882 (34.0)</td><td>15,156 (39.4)</td><td>0.65*</td></tr><tr><td></td><td>200 to 499</td><td>5832 (14.2)</td><td>313 (12.1)</td><td>5519 (14.3)</td><td></td></tr><tr><td></td><td>500 +</td><td>679 (1.7)</td><td>32 (1.2)</td><td>647 (1.7)</td><td></td></tr><tr><td></td><td>Not available</td><td>18,539 (45.1)</td><td>1364 (52.6)</td><td>17,175 (44.6)</td><td></td></tr><tr><td>BMI <i>n</i> (%)</td><td><18.5</td><td>15,258 (37.1)</td><td>882 (34.0)</td><td>14,376 (37.3)</td><td><0.01*</td></tr><tr><td></td><td>18.5 to 25</td><td>14,201 (34.6)</td><td>897 (34.6)</td><td>13,304 (34.6)</td><td></td></tr><tr><td></td><td>>25</td><td>1399 (3.4)</td><td>123 (4.8)</td><td>1276 (3.3)</td><td></td></tr><tr><td></td><td>Not available</td><td>10,230 (24.9)</td><td>689 (26.6)</td><td>9541 (24.8)</td><td></td></tr><tr><td>Region <i>n</i> (%)</td><td>Africa</td><td>9156 (22.3)</td><td>801 (30.9)</td><td>8355 (21.7)</td><td><0.01</td></tr><tr><td></td><td>Asia</td><td>31,698 (77.1)</td><td>1781 (68.7)</td><td>29,917 (77.7)</td><td></td></tr><tr><td></td><td>Europe</td><td>234 (0.6)</td><td>9 (0.4)</td><td>225 (1.0)</td><td></td></tr><tr><td>Duration of ART (years)</td><td>Median (IQR)</td><td>1.7 (0.6, 3.4)</td><td>1.4 (0.6, 2.9)</td><td>1.7 (0.6, 3.5)</td><td><0.01</td></tr></table> |
44923ae2ab75a413b83f49fbb4c6ea9e33cebce0bb96877e5f1bda69537ce227.png | simple | <table><tr><td>Test</td><td>Strain H-6</td><td><i>Alteromonas macleodii</i></td></tr><tr><td>Starch hydrolysis</td><td>+</td><td>+</td></tr><tr><td>Catalase</td><td>+</td><td>+</td></tr><tr><td>H<sub>2</sub>S production</td><td>+</td><td>+</td></tr><tr><td>Gelatin hydrolysis</td><td>+</td><td>+</td></tr><tr><td>Indole test</td><td>–</td><td>0</td></tr><tr><td>Methyl-red test</td><td>–</td><td>+</td></tr><tr><td>Voges-Proskauer test</td><td>–</td><td>–</td></tr><tr><td>Citrate utilization</td><td>–</td><td>0</td></tr><tr><td>Arginine utilization</td><td>+</td><td>0</td></tr><tr><td>Phenylalanine utilization</td><td>–</td><td>0</td></tr><tr><td>Glucose utilization</td><td>+</td><td>+</td></tr><tr><td>Lactose utilization</td><td>+</td><td>+</td></tr><tr><td>Sucrose utilization</td><td>+</td><td>+</td></tr><tr><td>Gram reaction</td><td>G<sup>−</sup></td><td>G<sup>−</sup></td></tr></table> |
2e7b4d125b8ec55d99e179d845a6bea6c2c4603f58aec7fdca4247b0a2a40bea.png | simple | <table><tr><td>Polymorphism</td><td>Cachexia <i>n</i> = 61 (%)</td><td>Noncachexia <i>n</i> = 64 (%)</td><td><i>χ</i><sup>2</sup></td><td><i>P</i></td></tr><tr><td>IL-8 −251 A/T</td><td></td><td></td><td>1.224</td><td>.542</td></tr><tr><td> AA</td><td>12 (19.7)</td><td>8 (12.5)</td><td></td><td></td></tr><tr><td> AT</td><td>34 (55.7)</td><td>38 (59.4)</td><td></td><td></td></tr><tr><td> TT</td><td>15 (24.6)</td><td>18 (28.1)</td><td></td><td></td></tr><tr><td> A allele</td><td>58 (47.5)</td><td>54 (42.2)</td><td>0.724</td><td>.395</td></tr><tr><td> T allele</td><td>64 (52.5)</td><td>74 (57.8)</td><td></td><td></td></tr><tr><td>IL-8 +781 C/T</td><td></td><td></td><td>9.315</td><td>.009</td></tr><tr><td> CC</td><td>13 (21.3)</td><td>27 (42.2)</td><td></td><td></td></tr><tr><td> CT</td><td>29 (47.5)</td><td> 29 (45.3)</td><td></td><td></td></tr><tr><td> TT</td><td>19 (31.2)</td><td>8 (12.5)</td><td></td><td></td></tr><tr><td> C allele</td><td>55 (45.1)</td><td>83 (64.8)</td><td></td><td></td></tr><tr><td> T allele</td><td>67 (54.9)</td><td> 45 (35.2)</td><td>9.864</td><td>.002</td></tr></table> |
ef5b05697f5e19c0711fc48a08d0ef04b38779d11ca62c34f799929356b1f198.png | complex | <table><tr><td></td><td></td><td colspan="3">2004</td><td colspan="3">2005</td></tr><tr><td></td><td></td><td>dry season</td><td>rainy season</td><td>global</td><td>dry season</td><td>rainy season</td><td>global</td></tr><tr><td>Data</td><td>Mean</td><td>0.390</td><td>0.311</td><td>0.351</td><td>0.166</td><td>0.212</td><td>0.190</td></tr><tr><td></td><td>SD<sup>&</sup></td><td>0.385</td><td>0.260</td><td>0.330</td><td>0.241</td><td>0.257</td><td>0.250</td></tr><tr><td>Kriging model</td><td></td><td>Ordinary</td><td>Ordinary</td><td>Ordinary</td><td>Ordinary</td><td>Universal</td><td>Ordinary</td></tr><tr><td>Transform data</td><td></td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Trend Removal</td><td></td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Searching Neighborhood</td><td>Radius (m)</td><td>9924.7</td><td>9509.9</td><td>9509.9</td><td>9924.7</td><td>9509.9</td><td>9924.7</td></tr><tr><td></td><td>Angle</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Prediction error measurements</td><td>Mean</td><td>0.021</td><td>0.005</td><td>0.012</td><td>0.005</td><td>0</td><td>-0.0004</td></tr><tr><td></td><td>MSE<sup>#</sup></td><td>0.435</td><td>0.302</td><td>0.338</td><td>0.157</td><td>0.113</td><td>0.102</td></tr><tr><td></td><td>Average Stand. Error</td><td>0.4</td><td>0.282</td><td>0.308</td><td>0.144</td><td>0.11</td><td>0.102</td></tr><tr><td></td><td>SMSE<sup>$</sup></td><td>1.09</td><td>1.074</td><td>1.098</td><td>1.088</td><td>1.015</td><td>1.006</td></tr></table> |
2e8fb8ef9f6ef4cf9921d42a8b32688b048d8e2b39f2cfec1e4e79966080b920.png | simple | <table><tr><td></td><td>Medical Costs</td><td>Costs per Hypoglycemia Event</td><td>Costs per Cardiovascular Events</td><td>Weight Gain Costs (transition costs<sup>a</sup>)</td><td>Total Costs (without transition costs<sup>a</sup>)</td></tr><tr><td>Metformin monotherapy</td><td>$24</td><td>$0</td><td>$141</td><td>$0</td><td>$165</td></tr><tr><td>Metformin+DPP-4i</td><td>$3524</td><td>$0</td><td>$330</td><td>$0</td><td>$3854</td></tr><tr><td>Metformin+DPP-4i + Basal insulin</td><td>$7170</td><td>$1</td><td>$366</td><td>$0</td><td>$7537</td></tr><tr><td>Metformin+SU</td><td>$40</td><td>$4</td><td>$441</td><td>$148</td><td>$486</td></tr><tr><td>Metformin+SU + Basal insulin</td><td>$3686</td><td>$1</td><td>$366</td><td>$0</td><td>$4054</td></tr></table> |
7098e1b82bd0ed2e256a3e2dc3824aaae86f3d457be52c6e21a92004462fe3a9.png | complex | <table><tr><td>Agricultural sector</td><td>Specific application areas</td><td>References</td></tr><tr><td rowspan="4">Agronomy/Horticulture</td><td>Crop protection</td><td>[2,33]</td></tr><tr><td>Cultivar selection & discrimination</td><td>[34,35,44]</td></tr><tr><td>Pesticide detection</td><td>[33,45–48]</td></tr><tr><td>Plant cell culture</td><td>[36]</td></tr><tr><td>Biotechnology processes</td><td>Monitoring</td><td>[49,50]</td></tr><tr><td rowspan="4">Botany</td><td>Floral odors</td><td>[37]</td></tr><tr><td>Plant identification</td><td>[30]</td></tr><tr><td>Plant volatiles detection</td><td>[30,38,39]</td></tr><tr><td>Taxonomic determinations</td><td>[30]</td></tr><tr><td>Cell culture</td><td>Plant growth</td><td>[36]</td></tr><tr><td rowspan="2">Chemistry</td><td>Chemical detection & identification</td><td>[51]</td></tr><tr><td>Classification</td><td>[52,53]</td></tr><tr><td rowspan="2">Ecology</td><td>Niche roles in ecosystem</td><td>[30]</td></tr><tr><td>Plant and animal species identification</td><td>[30]</td></tr><tr><td rowspan="2">Entomology</td><td>Detect insects or induced plant volatiles</td><td>[54–56]</td></tr><tr><td>Insect identification and plant damage</td><td>[57–61]</td></tr><tr><td rowspan="5">Environmental hazards</td><td>Ecosystem management</td><td>[30]</td></tr><tr><td>Explosive vapors</td><td>[62–64]</td></tr><tr><td>Health hazards monitoring</td><td>[5,65–70]</td></tr><tr><td>Toxic gas detection</td><td>[71–77]</td></tr><tr><td>Water contamination detection</td><td>[78–81]</td></tr><tr><td rowspan="2">Food production</td><td>Chemical contaminants</td><td>[82]</td></tr><tr><td>Microbial pathogens or toxins</td><td>[83,84]</td></tr><tr><td rowspan="3">Forestry/Silviculture</td><td>Classify/identify wood types</td><td>[30,85]</td></tr><tr><td>Forest health protection</td><td>[2,86]</td></tr><tr><td>Forest management</td><td>[30]</td></tr><tr><td rowspan="3">Industrial Processes</td><td>Process monitoring control</td><td>[87,88]</td></tr><tr><td>Formulation development</td><td>[89]</td></tr><tr><td>Quality control</td><td>[90]</td></tr><tr><td rowspan="5">Microbiology</td><td>Discrimination of strains</td><td>[91–95]</td></tr><tr><td>Identification of microbes</td><td>[96]</td></tr><tr><td>Microbial growth phases</td><td>[97]</td></tr><tr><td>Pathogen detection</td><td>[98]</td></tr><tr><td>Toxin production</td><td>[99]</td></tr><tr><td rowspan="5">Monitoring</td><td>Enzyme and protein activity</td><td>[100]</td></tr><tr><td>Humidity</td><td>[101,102]</td></tr><tr><td>Immunoglobulin levels</td><td>[103]</td></tr><tr><td>Oxygen levels</td><td>[104]</td></tr><tr><td>Plant volatiles</td><td>[39]</td></tr><tr><td rowspan="2">Physiological conditions</td><td>Disease effects on plant physiology</td><td>[31,32]</td></tr><tr><td>Fruits</td><td>[105]</td></tr><tr><td rowspan="9">Plant Pathology</td><td>Crop protection against bioterrorism</td><td>[2]</td></tr><tr><td>Disease detection and monitoring</td><td>[2,106–112]</td></tr><tr><td>Host identification</td><td>[30,85]</td></tr><tr><td>Host physiology (pathogenesis effects)</td><td>[31,32,105]</td></tr><tr><td>Host resistance</td><td>[113]</td></tr><tr><td>Pathogen identification</td><td>[2,106]</td></tr><tr><td>Post-harvest decay or rot detection</td><td>[114–118]</td></tr><tr><td>Wood decay fungi</td><td>[2,86,96,119,120]</td></tr><tr><td>Wood decay types</td><td>[2,86]</td></tr><tr><td>Waste management</td><td>Monitoring malodorous emissions</td><td>[23,121–125]</td></tr><tr><td>Wood science</td><td>Wood identifications</td><td>[30,85,126]</td></tr></table> |
263d9a1c311d4db0b694cdff451f0da2a579bec326191751ecff62a54767fec6.png | simple | <table><tr><td>Pathways</td><td>Map B</td><td>No. of genes</td><td>No. of TFs</td></tr><tr><td>00010: Glycolysis/gluconeogenesis</td><td>Carbohydrate metabolism</td><td>57</td><td>14</td></tr><tr><td>00500: Starch and sucrose metabolism</td><td>Carbohydrate metabolism</td><td>32</td><td>12</td></tr><tr><td>00520: Amino sugar and nucleotide sugar metabolism</td><td>Carbohydrate metabolism</td><td>48</td><td>20</td></tr><tr><td>00620: Pyruvate metabolism</td><td>Carbohydrate metabolism</td><td>39</td><td>22</td></tr><tr><td>00030: Pentose phosphate pathway</td><td>Carbohydrate metabolism</td><td>25</td><td>14</td></tr><tr><td>00630: Glyoxylate and dicarboxylate metabolism</td><td>Carbohydrate metabolism</td><td>18</td><td>30</td></tr><tr><td>00250: Alanine, aspartate and glutamate metabolism</td><td>Amino acid metabolism</td><td>32</td><td>22</td></tr><tr><td>00290: Valine, leucine and isoleucine biosynthesis</td><td>Amino acid metabolism</td><td>11</td><td>30</td></tr><tr><td>00310: Lysine degradation</td><td>Amino acid metabolism</td><td>43</td><td>26</td></tr><tr><td>00230: Purine metabolism</td><td>Nucleotide metabolism</td><td>152</td><td>24</td></tr><tr><td>00590: Arachidonic acid metabolism</td><td>Lipid metabolism</td><td>77</td><td>21</td></tr><tr><td>00591: Linoleic acid metabolism</td><td>Lipid metabolism</td><td>40</td><td>13</td></tr><tr><td>00100: Steroid biosynthesisa</td><td>Lipid metabolism</td><td>18</td><td>17</td></tr><tr><td>00670: One carbon pool by folate</td><td>Metabolism of cofactors and vitamins</td><td>17</td><td>26</td></tr><tr><td>00790: Folate biosynthesisa</td><td>Metabolism of cofactors and vitamins</td><td>11</td><td>28</td></tr><tr><td>00900: Terpenoid backbone biosynthesisa</td><td>Metabolism of terpenoids and polyketides</td><td>13</td><td>22</td></tr><tr><td>00604: Glycosphingolipid biosynthesis-ganglio seriesa</td><td>Glycan biosynthesis and metabolism</td><td>15</td><td>19</td></tr><tr><td>00534: Glycosaminoglycan biosynthesis-heparan sulfate</td><td>Glycan biosynthesis and metabolism</td><td>24</td><td>25</td></tr></table> |
8a9fe09d2a779fce9004a46e795f714353837202c9f5d8cd6f7082bf00c4e314.png | simple | <table><tr><td>Contig_ID</td><td>Log2_Fold_change</td><td>Adj<i>P</i>_value</td><td>2C FPKM</td><td>2 T FPKM</td><td>E-value</td><td>Protein families</td></tr><tr><td>c32642_g1_i1</td><td>-3.614</td><td>0.0009</td><td>3.1</td><td>0.3</td><td>0</td><td>Glycosyltransferase 8 family, Glycogenin subfamily</td></tr><tr><td>c38916_g2_i3</td><td>-3.232</td><td>0.0097</td><td>2.9</td><td>0.3</td><td>1.00E-83</td><td>Cyclin family, Cyclin AB subfamily</td></tr><tr><td>c44152_g1_i2</td><td>-2.667</td><td>0.0177</td><td>3.8</td><td>0.6</td><td>0</td><td>Cyclic nucleotide-gated cation channel family</td></tr><tr><td>c37946_g1_i2</td><td>-2.916</td><td>0.0244</td><td>4.1</td><td>0.6</td><td>1.00E-132</td><td>MAD2 family</td></tr><tr><td>c43673_g1_i5</td><td>-2.574</td><td>0.0313</td><td>4.8</td><td>0.8</td><td>0</td><td>Cytochrome P450 family</td></tr><tr><td>c44152_g1_i1</td><td>-2.545</td><td>0.0818</td><td>3.1</td><td>0.6</td><td>0</td><td>Cyclic nucleotide-gated cation channel family</td></tr><tr><td>c24995_g1_i1</td><td>-2.173</td><td>0.1794</td><td>2.8</td><td>0.7</td><td>0</td><td>WD repeat CDC20/Fizzy family</td></tr><tr><td>c25920_g1_i1</td><td>-2.094</td><td>0.2470</td><td>3.7</td><td>0.9</td><td>6.00E-162</td><td>NA</td></tr><tr><td>c33730_g1_i3</td><td>-1.879</td><td>0.3855</td><td>2.3</td><td>0.7</td><td>6.00E-96</td><td>HSF family, Class A subfamily</td></tr></table> |
eb65959ecdfbbfb273f674f5e294444d389c79a595fc5c6dd9c49a946ee813ac.png | complex | <table><tr><td></td><td>WC</td><td>BMI</td><td>PBF</td><td>HDL</td><td>Triglyceride</td><td>LDL</td><td>SBP</td><td>DBP</td></tr><tr><td colspan="9">Females</td></tr><tr><td> 8 year old cohort</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td></td><td></td><td></td></tr><tr><td> 11 year old cohort</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td></td><td></td><td></td></tr><tr><td> 14 year old cohort</td><td></td><td><.05</td><td><.05</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="9">Males</td></tr><tr><td> 8 year old cohort</td><td><.05</td><td><.05</td><td><.05</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 11 year old cohort</td><td><.05</td><td><.05</td><td><.05</td><td></td><td><.05</td><td><.05</td><td><.05</td><td></td></tr><tr><td> 14 year old cohort</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td><.05</td><td></td><td></td></tr></table> |
03dbc004996232f1fef9b0497717ad01758a18c5ec0785b081cfd2fc85b9c9ae.png | simple | <table><tr><td>Causes of death</td><td>Number of deathsn (%)</td><td>Cause-Specific Mortality Rate (per 1000 people)</td></tr><tr><td>Ch. X – Diseases of the respiratory system, J00-J99</td><td>282 (37.1)</td><td>3187</td></tr><tr><td>Ch. IX – Diseases of the circulatory system, I00-I99</td><td>197 (25.9)</td><td>2227</td></tr><tr><td>Ch. V – Mental and behavioural disorders, F00-F99</td><td>81 (10.7)</td><td>916</td></tr><tr><td>Ch. VI – Diseases of the nervous system, G00-G99</td><td>59 (7.8)</td><td>669</td></tr><tr><td>Ch. I – Certain infectious and parasitic diseases, A00-B99</td><td>33 (4.3)</td><td>373</td></tr><tr><td>Ch. XVIII – Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, R00-R99</td><td>28 (3.7)</td><td>317</td></tr><tr><td>Ch. XI – Diseases of the digestive system, K00-K93</td><td>16 (2.1)</td><td>181</td></tr><tr><td>Ch. II – Neoplasms, C00-D48</td><td>15 (2)</td><td>170</td></tr><tr><td>Ch. IV – Endocrine, nutritional and metabolic diseases, E00-E90</td><td>14 (1.8)</td><td>158</td></tr><tr><td>Ch. XIV – Diseases of the genitourinary system, N00-N99</td><td>10 (1.3)</td><td>113</td></tr><tr><td>Ch. XVII – Congenital malformations, deformations and chromosomal abnormalities, Q00-Q99</td><td>9 (1.2)</td><td>102</td></tr><tr><td>Ch. XX – External causes of morbidity and mortality, V01-Y98</td><td>8 (1.1)</td><td>90</td></tr><tr><td>Ch. III – Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, D50-D89</td><td>3 (0.4)</td><td>34</td></tr><tr><td>Ch. XIX – Injury, poisoning and certain other consequences of external causes, S00-T98</td><td>3 (0.4)</td><td>34</td></tr><tr><td>Ch. XIII – Diseases of the musculoskeletal system and connective tissue, M00-M99</td><td>2 (0.3)</td><td>23</td></tr><tr><td>Ch. XII – Diseases of the skin and subcutaneous tissue, L00-L99</td><td>0 (0)</td><td>NA</td></tr><tr><td>Ch. XVI - Certain conditions originating in the perinatal period, P00-P96</td><td>0 (0)</td><td>NA</td></tr></table> |
1cbedbd60043a082d02732ebc507ff1e30733e1e75fc77983773c03603d625e5.png | complex | <table><tr><td rowspan="2">Case</td><td rowspan="2">Measure</td><td colspan="2">Improvement</td><td colspan="2">Execution time</td></tr><tr><td>Standard</td><td>Scout</td><td>Standard</td><td>Scout</td></tr><tr><td rowspan="5">I</td><td>Average</td><td>47.36%</td><td>57.21%</td><td>2.0065</td><td>1.2346</td></tr><tr><td>Stdev</td><td>0.2443</td><td>0.3037</td><td>1.8070</td><td>0.7588</td></tr><tr><td>Observations</td><td>480</td><td>480</td><td>480</td><td>480</td></tr><tr><td><i>z</i>-score</td><td colspan="2">−5.5393</td><td colspan="2">8.6285</td></tr><tr><td><i>P</i> value</td><td colspan="2">0.0000</td><td colspan="2">0.0000</td></tr><tr><td rowspan="5">II</td><td>Average</td><td>62.99%</td><td>81.34%</td><td>839.9745</td><td>741.0001</td></tr><tr><td>Stdev</td><td>0.3015</td><td>0.4073</td><td>295.65</td><td>338.65</td></tr><tr><td>Observations</td><td>160</td><td>160</td><td>160</td><td>160</td></tr><tr><td><i>z</i>-score</td><td colspan="2">−4.5795</td><td colspan="2">2.7849</td></tr><tr><td><i>P</i> value</td><td colspan="2">0.0000</td><td colspan="2">0.0054</td></tr></table> |
d6653c6ea89f0c13d6a70e69172b2c0cdb9235a686c268a8f4104a8b6766d17c.png | complex | <table><tr><td rowspan="2">Sample ID</td><td colspan="3"><i>AR</i>W742C (TGg>TGt/c)ddPCRNEB Phusion<sup>®</sup> Preamplification</td><td colspan="3"><i>AR</i>W742C (TGg>TGt/c)ddPCRInvitrogenTM PlatinumTM SuperFiTM Preamplification</td></tr><tr><td>Mutant Droplet Count</td><td>Wild-type Droplet Count</td><td>Percent Mutant</td><td>Mutant Droplet Count</td><td>Wild-type Droplet Count</td><td>Percent Mutant</td></tr><tr><td>JHU Pt 3</td><td>4</td><td>25067</td><td>0.016</td><td>38</td><td>33611</td><td>0.113</td></tr><tr><td>JHU Pt 7</td><td>0</td><td>19753</td><td>0.000</td><td>0</td><td>15958</td><td>0.000</td></tr><tr><td>PreamplifiedWild-type Genomic DNA</td><td>0</td><td>17573</td><td>0.000</td><td>0</td><td>37069</td><td>0.000</td></tr><tr><td>PreamplifiedNo Template Control</td><td>0</td><td>0</td><td>0.000</td><td>0</td><td>0</td><td>0.000</td></tr><tr><td>Non-AmplifiedWild-type Genomic DNA</td><td>0</td><td>31225</td><td>0.000</td><td>0</td><td>31225</td><td>0.000</td></tr><tr><td>Non-Amplified<i>AR</i> W742C Mutant Control DNA</td><td>10602</td><td>0</td><td>100</td><td>10602</td><td>0</td><td>100</td></tr><tr><td>Non-AmplifiedNo Template Control</td><td>0</td><td>0</td><td>0.000</td><td>0</td><td>0</td><td>0.000</td></tr></table> |
41cd3aa8f4955df3da17f85f92559b0c9db379487dd73fe597ee539ab41b1342.png | simple | <table><tr><td>Line</td><td>Ca (%)</td><td>K (%)</td><td>Mg (%)</td><td>P (%)</td><td>N (%)</td><td>S (%)</td><td>B (mg/kg)</td><td>Cu (mg/kg)</td><td>Fe (mg/kg)</td><td>Mn (mg/kg)</td><td>Mo (mg/kg)</td><td>Na (mg/kg)</td><td>Zn (mg/kg)</td></tr><tr><td>243</td><td>2.2</td><td>1.4</td><td>0.5</td><td>0.2</td><td>1.3</td><td>0.5</td><td>126</td><td>8.0</td><td>54.9</td><td>52.5</td><td>1.9</td><td>5386</td><td>16.4</td></tr><tr><td>56F</td><td>2.7</td><td>1.6</td><td>0.5</td><td>0.2</td><td>1.5</td><td>0.8</td><td>131</td><td>8.2</td><td>59.4</td><td>51.4</td><td>1.1</td><td>6234</td><td>16.8</td></tr><tr><td>56N</td><td>2.6</td><td>1.4</td><td>0.5</td><td>0.3</td><td>1.5</td><td>0.7</td><td>145</td><td>7.9</td><td>57.9</td><td>49.9</td><td>1.3</td><td>5317</td><td>16.3</td></tr><tr><td>DESF</td><td>1.3</td><td>1.3</td><td>0.3</td><td>0.2</td><td>1.5</td><td>0.6</td><td>148</td><td>7.6</td><td>56.1</td><td>44.8</td><td>1.3</td><td>4970</td><td>15.3</td></tr><tr><td>DESN</td><td>1.9</td><td>1.3</td><td>0.3</td><td>0.2</td><td>1.4</td><td>0.5</td><td>144</td><td>8.2</td><td>48.5</td><td>51.4</td><td>1.4</td><td>51.4</td><td>16.6</td></tr><tr><td>MDF</td><td>1.5</td><td>1.3</td><td>0.4</td><td>0.2</td><td>1.7</td><td>0.5</td><td>125</td><td>7.5</td><td>46.9</td><td>55.3</td><td>1.2</td><td>3926</td><td>15.9</td></tr><tr><td>MDN</td><td>2.8</td><td>2.4</td><td>0.6</td><td>0.2</td><td>2.2</td><td>0.9</td><td>148</td><td>7.6</td><td>60.4</td><td>87.8</td><td>1.2</td><td>4936</td><td>15.4</td></tr><tr><td>SGF</td><td>1.4</td><td>2.5</td><td>0.6</td><td>0.2</td><td>1.6</td><td>0.4</td><td>82</td><td>8.0</td><td>41.4</td><td>61.9</td><td>1.3</td><td>4711</td><td>15.9</td></tr><tr><td>SGN</td><td>1.6</td><td>2.5</td><td>0.4</td><td>0.2</td><td>1.8</td><td>0.4</td><td>68</td><td>7.8</td><td>47.5</td><td>55.9</td><td>1.3</td><td>4627</td><td>14.3</td></tr><tr><td>STVF</td><td>1.5</td><td>1.1</td><td>0.3</td><td>0.1</td><td>2.3</td><td>0.4</td><td>81</td><td>7.7</td><td>50.1</td><td>68.5</td><td>1.4</td><td>4627</td><td>14.4</td></tr><tr><td>STVN</td><td>1.7</td><td>1.3</td><td>0.7</td><td>0.3</td><td>2.8</td><td>0.9</td><td>85</td><td>7.9</td><td>64.8</td><td>110.0</td><td>1.3</td><td>6350</td><td>14.3</td></tr><tr><td>LSD</td><td>0.16</td><td>0.09</td><td>0.04</td><td>0.02</td><td>0.15</td><td>0.08</td><td>5</td><td>0.43</td><td>2.9</td><td>3.6</td><td>0.15</td><td>360</td><td>0.6</td></tr></table> |
f5452c5811688ef4b1d28afe1d5057ead27c65f3e016fb34fbc32f333ce2704c.png | simple | <table><tr><td>Domain</td><td>Principal cause</td><td>Number of patients</td></tr><tr><td>Neuromuscular</td><td>Parkinsonism syndrome</td><td>3</td></tr><tr><td></td><td>Unexplained Ataxia</td><td>2</td></tr><tr><td></td><td>Lower extremity weakness</td><td>7</td></tr><tr><td>Sensory</td><td>Dizziness or vertigo</td><td>2</td></tr><tr><td></td><td>Visual impairment</td><td>4</td></tr><tr><td></td><td>Peripheral neuropathy</td><td>3</td></tr><tr><td>Orthopedics</td><td>Osteoarthritis (including foot problems)</td><td>8</td></tr><tr><td></td><td>Hip problems or deformity</td><td>6</td></tr><tr><td>CV causes*</td><td>Orthostatic hypotension</td><td>2</td></tr><tr><td></td><td>Postprandial hypotension</td><td>1</td></tr><tr><td></td><td>Vasovagal syndrome</td><td>2</td></tr><tr><td></td><td>Carotid sinus hypersensitivity</td><td>1</td></tr></table> |
5195299103baca653e98863703fc1981f035050e892129a09a792957b283cd71.png | simple | <table><tr><td></td><td>RECIST</td><td>CHOI</td><td>mCHOI</td><td>MASS</td></tr><tr><td>Progressive disease (MASS unfavourable response)</td><td>Increase in sum of longest target lesion diameters >20%.orDevelopment of new lesions.orUnequivocal non-target lesion progression.</td><td>Increase in lesion size<sup>a</sup> > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.</td><td>Increase in lesion size<sup>a</sup> > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.</td><td>Increase in lesion size<sup>a</sup> > 20% without central necrosis.orDevelopment of new lesions.orNew intratumoral enhancing components.</td></tr><tr><td>Partial response (MASS favourable response)</td><td>>30% decrease in sum of longest target lesion diameters.</td><td>Decrease in target lesion CT enhancement (Hounsfield units) >15% <i>or</i> size >10%</td><td>Decrease in target lesion CT enhancement (Hounsfield units) >15% <i>and</i> size >10%</td><td>Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units</td></tr><tr><td>Complete response</td><td>Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm).</td><td>Disappearance of all target lesions</td><td>Disappearance of all target lesions</td><td>Disappearance of all target lesions</td></tr><tr><td>Stable disease (MASS indeterminate response)</td><td>None of the above</td><td>None of the above</td><td>None of the above</td><td>None of the above</td></tr></table> |
a4e401b6d61905f718123d62f42dc48d4a26d8dd0ca0342912ca7e8c702113f6.png | complex | <table><tr><td>Indicator bacteria</td><td>Station</td><td>N</td><td>Mean</td><td>Std. Deviation</td><td>Minimum</td><td>Maximum</td></tr><tr><td rowspan="8">Total coliform (MPN/100 ml)</td><td>1</td><td>6</td><td><underline>800</underline></td><td>112.07</td><td>600</td><td>920</td></tr><tr><td>2</td><td>6</td><td>1220</td><td>184.93</td><td>920</td><td>1400</td></tr><tr><td>3</td><td>6</td><td>1000</td><td>161.12</td><td>680</td><td>1100</td></tr><tr><td>4</td><td>6</td><td>1050</td><td>168.99</td><td>750</td><td>1200</td></tr><tr><td>5</td><td>6</td><td><i>1800</i></td><td>328.00</td><td>1200</td><td>2200</td></tr><tr><td>6</td><td>6</td><td>1750</td><td>339.76</td><td>1100</td><td>2000</td></tr><tr><td>7</td><td>6</td><td>885</td><td>111.23</td><td>660</td><td>950</td></tr><tr><td>8</td><td>6</td><td>1400</td><td>247.54</td><td>920</td><td>1600</td></tr><tr><td>Average</td><td></td><td>48</td><td>1238.12</td><td>206.7</td><td>853.75</td><td>1421.25</td></tr><tr><td rowspan="8">Fecal coliform (MPN/100 ml)</td><td>1</td><td>6</td><td><underline>103.67</underline></td><td>15.57</td><td>79</td><td>120</td></tr><tr><td>2</td><td>6</td><td>165</td><td>8.07</td><td>160</td><td>180</td></tr><tr><td>3</td><td>6</td><td>111.17</td><td>17.11</td><td>94</td><td>140</td></tr><tr><td>4</td><td>6</td><td>143.33</td><td>20.15</td><td>110</td><td>170</td></tr><tr><td>5</td><td>6</td><td><i>213.33</i></td><td>72.67</td><td>110</td><td>330</td></tr><tr><td>6</td><td>6</td><td>193.33</td><td>43.29</td><td>140</td><td>260</td></tr><tr><td>7</td><td>6</td><td>107.17</td><td>16.29</td><td>79</td><td>130</td></tr><tr><td>8</td><td>6</td><td>170</td><td>38.14</td><td>110</td><td>230</td></tr><tr><td colspan="2">Average</td><td>48</td><td>150.875</td><td>28.91125</td><td>110.25</td><td>195</td></tr><tr><td rowspan="8">Pseudomonas (MPN/100 ml)</td><td>1</td><td>6</td><td><underline>4.50</underline></td><td>1.22</td><td>3</td><td>6</td></tr><tr><td>2</td><td>6</td><td>8.50</td><td>2.07</td><td>5</td><td>11</td></tr><tr><td>3</td><td>6</td><td>6.33</td><td>2.16</td><td>3</td><td>9</td></tr><tr><td>4</td><td>6</td><td>7.33</td><td>2.58</td><td>4</td><td>11</td></tr><tr><td>5</td><td>6</td><td><i>13.00</i></td><td>2.28</td><td>11</td><td>17</td></tr><tr><td>6</td><td>6</td><td>11.00</td><td>1.414</td><td>9</td><td>13</td></tr><tr><td>7</td><td>6</td><td>4.83</td><td>1.169</td><td>3</td><td>6</td></tr><tr><td>8</td><td>6</td><td>10.33</td><td>1.966</td><td>7</td><td>12</td></tr><tr><td colspan="2">Average</td><td>48</td><td>8.227</td><td>1.857</td><td>5.625</td><td>10.625</td></tr><tr><td rowspan="8">HPC (CFU/ml)</td><td>1</td><td>6</td><td><underline>1150.00</underline></td><td>89.443</td><td>1000</td><td>1250</td></tr><tr><td>2</td><td>6</td><td>1841.67</td><td>724.166</td><td>1100</td><td>2800</td></tr><tr><td>3</td><td>6</td><td>1350.00</td><td>420.095</td><td>940</td><td>1850</td></tr><tr><td>4</td><td>6</td><td>1743.33</td><td>406.776</td><td>1350</td><td>2500</td></tr><tr><td>5</td><td>6</td><td><i>2358.33</i></td><td>941.497</td><td>1500</td><td>3500</td></tr><tr><td>6</td><td>6</td><td>2173.33</td><td>344.770</td><td>1890</td><td>2700</td></tr><tr><td>7</td><td>6</td><td>1248.33</td><td>217.754</td><td>970</td><td>1610</td></tr><tr><td>8</td><td>6</td><td>2078.33</td><td>302.815</td><td>1640</td><td>2400</td></tr><tr><td colspan="2">Average</td><td>48</td><td>1742.91</td><td>430.914</td><td>1298.75</td><td>2326.25</td></tr></table> |
1a30a2094c5232554835f1d043c375acb4e16640ae6139e345e5fdb4eda31f2a.png | complex | <table><tr><td rowspan="2">Whole sample size (N = 47)</td><td colspan="4">Placebo</td><td colspan="4">Perilla</td><td>Placebo</td><td>Perilla</td><td> </td></tr><tr><td>Run In</td><td>Intake week 1-2</td><td>Intake week 3-4</td><td>p value (ANOVA)</td><td>Run In</td><td>Intake week 1-2</td><td>Intake week 3-4</td><td>p value (ANOVA)</td><td>Delta week 3-4 to run in</td><td>Delta week 3-4 to run in</td><td>Comparison between groups (95% CI)</td></tr><tr><td>Bloating</td><td>1.45</td><td>1.44</td><td>1.2</td><td>0.0733</td><td>1.42</td><td>1.28</td><td>0.98</td><td>0.0003</td><td>-0.25</td><td>-0.44</td><td rowspan="2">-0.194 to 0.562</td></tr><tr><td>SD</td><td>0.74</td><td>0.72</td><td>0.77</td><td> </td><td>0.81</td><td>0.64</td><td>0.78</td><td> </td><td>0.71</td><td>0.56</td></tr><tr><td>Passage of gas</td><td>1.47</td><td>1.57</td><td>1.37</td><td>0.2284</td><td>1.6</td><td>1.5</td><td>1.3</td><td>0.0264</td><td>-0.10</td><td>-0.30</td><td rowspan="2">-0.177 to 0.577</td></tr><tr><td>SD</td><td>0.66</td><td>0.53</td><td>0.62</td><td> </td><td>0.77</td><td>0.62</td><td>0.74</td><td> </td><td>0.62</td><td>0.66</td></tr><tr><td>GI rumbling</td><td>1.51</td><td>1.33</td><td>1.18</td><td>0.0635</td><td>1.64</td><td>1.27</td><td>1.09</td><td>0.0014</td><td>-0.33</td><td>-0.55</td><td rowspan="2">-0.251 to 0.685</td></tr><tr><td>SD</td><td>0.86</td><td>0.91</td><td>0.83</td><td> </td><td>0.85</td><td>0.6</td><td>0.81</td><td> </td><td>0.71</td><td>0.87</td></tr><tr><td>Feeling of fullness</td><td>1.08</td><td>1.05</td><td>0.83</td><td>0.0987</td><td>1.03</td><td>0.84</td><td>0.67</td><td>0.0152</td><td>-0.24</td><td>-0.36</td><td rowspan="2">-0.288 to 0.515</td></tr><tr><td>SD</td><td>0.8</td><td>0.59</td><td>0.62</td><td> </td><td>0.77</td><td>0.63</td><td>0.63</td><td> </td><td>0.64</td><td>0.72</td></tr><tr><td>Abdominal discomfort</td><td>1.15</td><td>1.06</td><td>0.84</td><td>0.0345</td><td>1.25</td><td>0.92</td><td>0.71</td><td>0.0004</td><td>-0.31</td><td>-0.54</td><td rowspan="2">-0.156 to 0.621</td></tr><tr><td>SD</td><td>0.93</td><td>0.84</td><td>0.81</td><td> </td><td>0.86</td><td>0.61</td><td>0.74</td><td> </td><td>0.55</td><td>0.75</td></tr></table> |
dba1e653b5941a54727a062fb863b12e5b46552320b3b9568d70f148dff55816.png | complex | <table><tr><td></td><td></td><td></td><td></td><td colspan="5">k-spaced AA pairs</td></tr><tr><td>Feature representation</td><td>Composition Vector</td><td>PSI-BLAST profile</td><td>Binary Encoding</td><td>adjacent pairs (dipeptides)</td><td>1-spaced pairs</td><td>......</td><td><i>p</i>-spaced pairs</td><td>Total</td></tr><tr><td>Number of features</td><td>20</td><td>315</td><td>380</td><td>400</td><td>400</td><td>......</td><td>400</td><td>400(<i>p</i>+1)</td></tr></table> |
4b2c641929eb94e73c79ac608a0ef26ed06c1a09ec5a9ae5eeebac3231a21250.png | simple | <table><tr><td>Haplotype</td><td>Cases (percentage)</td><td>Controls (percentage)</td><td>OR (95% CI)<sup>a</sup></td></tr><tr><td>z1 G-G-T-T-A</td><td>1,250 (49.4)</td><td>1,691 (48.2)</td><td>1.00 (reference)</td></tr><tr><td>z2 G-G-T-C-A</td><td>435 (17.2)</td><td>667 (19.0)</td><td>0.84 (0.72–0.98)</td></tr><tr><td>z3 G-C-T-T-A</td><td>403 (15.9)</td><td>544 (15.5)</td><td>0.99 (0.85–1.17)</td></tr><tr><td>z4 C-G-G-C-A</td><td>358 (14.1)</td><td>507 (14.5)</td><td>0.92 (0.79–1.09)</td></tr><tr><td>z5 C-G-G-C-G</td><td>53 (2.1)</td><td>63 (1.8)</td><td>1.16 (0.78–1.72)</td></tr><tr><td></td><td></td><td></td><td>Global <i>p </i>= 0.15</td></tr></table> |
995c5316fb3f1f8652c6267ba7e737757d93e5444c93d2e071fa69b50b73f8fd.png | complex | <table><tr><td>Ingredient</td><td>Herb medicine</td><td>Object</td><td>Stimulus</td><td>Role</td><td>related pathway</td></tr><tr><td>1, 6-di-O-caffeoyl-<i>β</i>-D-glucopyranoside</td><td>Callicarpa nudiflora Hook</td><td>Platelet</td><td>ADP, AA</td><td><i>α</i>IIb<i>β</i>3, 5-HT, TXA2, platelet aggregation↓</td><td>PI3K/Akt/GSK3<i>β</i>, RhoA</td></tr><tr><td>Atractylenolide</td><td>Atractylodes macrocephala</td><td>Platelet</td><td>ADP, collagen, thrombin</td><td>platelet aggregation and secretion↓</td><td>p38, PI3K/Akt</td></tr><tr><td rowspan="2">Andrographolide</td><td rowspan="2">Andrographis paniculata</td><td rowspan="2">Platelet</td><td rowspan="2">Collagen</td><td>platelet aggregation, Ca2+, TxB2↓</td><td>eNOS/NO/sGC/cGMP, PI3K/Akt/p38/cPLA2, PLC<i>γ</i>2/DAG/PKC</td></tr><tr><td>platelet aggregation, Ca2+↓</td><td>eNOS/NO/sGC/cGMP, p38/ROS/IKK<i>β</i>/NF-<i>κ</i>B/ERK2</td></tr><tr><td>Gomisin J</td><td>Schisandra chinensis</td><td>EC</td><td>None</td><td>eNOS, NO↑</td><td>Ca2+/CaMI, PI3K/Akt</td></tr><tr><td><i>β</i>-Elemene</td><td>Curcuma Wenyujin</td><td>EC</td><td>None</td><td>eNOS, NO↑</td><td>PI3K/Akt</td></tr><tr><td>Puerarin</td><td>Pueraria lobata</td><td>EC</td><td>TNF-<i>α</i></td><td>eNOS, NO↑</td><td>ER/PI3K/Akt, CaMKII/AMPK</td></tr><tr><td rowspan="3">Tanshinone IIA</td><td rowspan="3">Salvia miltiorrhiza Bunge</td><td>Macrophage</td><td>Ox-LDL</td><td>TF↓</td><td>ROS/NF-<i>κ</i>B</td></tr><tr><td>Platelet</td><td>None</td><td>Platelet activation↓</td><td>ER<i>α</i>/PI3K/Akt</td></tr><tr><td>Platelet</td><td>ADP</td><td>Platelet activation↓</td><td>ERK-2</td></tr><tr><td>Xuezhikang</td><td>Red yeast rice</td><td>Macrophage</td><td>Ox-LDL</td><td>TF↓, SOD↑</td><td>NOX/ROS/ERK1/2/NF-<i>κ</i>B</td></tr><tr><td>Gypenoside XLIX</td><td>Gynostemma pentaphyllum</td><td>Macrophage</td><td>LPS</td><td>TF↓</td><td>PPAR-<i>α</i></td></tr><tr><td>Salvianolic acid B</td><td>Salvia miltiorrhiza Bunge</td><td>EC</td><td>TNF-<i>α</i></td><td>PAI-1↓</td><td>ERK1/2/AP-1 (NF-<i>κ</i>B)</td></tr></table> |
8919b0d2f6d9a5f24354560b9574a407c4eec65253d16169b9e73b765f56a4a2.png | complex | <table><tr><td></td><td colspan="3">Incremental cost</td><td colspan="3">Incremental effect</td><td rowspan="2">ICER</td></tr><tr><td></td><td colspan="3">Mean; (95% bootstrap CI)</td><td colspan="3">Mean; (95% bootstrap CI)</td></tr><tr><td colspan="8">CBT versus TAU</td></tr><tr><td colspan="2">Completers (<i>N</i>=152)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>−2,061.9</td><td>−3,168.9</td><td>−954.9</td><td>0.01</td><td>−0.00</td><td>0.03</td><td>CBT dominant</td></tr><tr><td>EQ VAS</td><td>−2,073.2</td><td>−3,179.8</td><td>−966.6</td><td>6.19</td><td>3.63</td><td>8.75</td><td>CBT dominant</td></tr><tr><td>ITT (<i>N</i>=168)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>−2,158.8</td><td>−3,357.1</td><td>−960.5</td><td>0.02</td><td>−0.00</td><td>0.03</td><td>CBT dominant</td></tr><tr><td>EQ VAS</td><td>−2,163.9</td><td>−3,363.8</td><td>−964.0</td><td>6.33</td><td>3.62</td><td>9.07</td><td>CBT dominant</td></tr><tr><td colspan="2">PPA (<i>N</i>=154)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>−2,368.9</td><td>−3,599.1</td><td>−1,138.6</td><td>0.02</td><td>−0.00</td><td>0.03</td><td>CBT dominant</td></tr><tr><td>EQ VAS</td><td>−2,372.4</td><td>−3,604.8</td><td>−1,140.0</td><td>6.58</td><td>3.83</td><td>9.33</td><td>CBT dominant</td></tr><tr><td colspan="8">CBT versus RPT</td></tr><tr><td colspan="2">Completers (<i>N</i>=152)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>−2,386.9</td><td>−3,485.4</td><td>−1,288.3</td><td>0.01</td><td>−0.00</td><td>0.03</td><td>CBT dominant</td></tr><tr><td>EQ VAS</td><td>−2,393.9</td><td>−3,495.2</td><td>−1,292.6</td><td>3.52</td><td>1.13</td><td>5.90</td><td>CBT dominant</td></tr><tr><td>ITT (<i>N</i>=168)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>−2,304.7</td><td>−3,326.6</td><td>−1,282.7</td><td>0.01</td><td>−0.00</td><td>0.03</td><td>CBT dominant</td></tr><tr><td>EQ VAS</td><td>−2,307.8</td><td>−3,331.4</td><td>−1,284.2</td><td>3.61</td><td>1.08</td><td>6.15</td><td>CBT dominant</td></tr><tr><td colspan="2">PPA (<i>N</i>=154)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>−2,550.3</td><td>−3,624.9</td><td>−1,475.7</td><td>0.01</td><td>−0.00</td><td>0.03</td><td>CBT dominant</td></tr><tr><td>EQ VAS</td><td>−2,552.7</td><td>−3,631.5</td><td>−1,473.9</td><td>3.93</td><td>1.35</td><td>6.51</td><td>CBT dominant</td></tr><tr><td colspan="8">RPT versus TAU</td></tr><tr><td>Completers (<i>N</i>=152)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>324.9</td><td>−894.8</td><td>1,544.7</td><td>−0.00</td><td>−0.02</td><td>0.01</td><td>TAU dominant</td></tr><tr><td>EQ VAS</td><td>320.7</td><td>−894.3</td><td>1,535.6</td><td>2.67</td><td>0.56</td><td>4.79</td><td>120</td></tr><tr><td>ITT (<i>N</i>=168)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>145.9</td><td>−1,150.7</td><td>1,442.5</td><td>0.00</td><td>−0.01</td><td>0.02</td><td>79,071</td></tr><tr><td>EQ VAS</td><td>143.9</td><td>−1,150.8</td><td>1,438.6</td><td>2.72</td><td>0.42</td><td>5.02</td><td>53</td></tr><tr><td colspan="2">PPA (<i>N</i>=154)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>QALY (EQ-5D)</td><td>181.4</td><td>−1,127.9</td><td>1,490.7</td><td>0.00</td><td>−0.01</td><td>0.02</td><td>137,161</td></tr><tr><td>EQ VAS</td><td>180.3</td><td>−1,127.3</td><td>1,487.9</td><td>2.65</td><td>0.36</td><td>4.94</td><td>68</td></tr></table> |
d2886a2f51fe8dabe25ed74486238d56d4c960e22726af646ceeab6c0689d0f9.png | simple | <table><tr><td>Flavonoid</td><td>NGF</td><td>GDNF</td><td>BDNF</td></tr><tr><td>Flavanones</td><td> </td><td> </td><td> </td></tr><tr><td> Alpinetin</td><td>+++</td><td>++</td><td>+</td></tr><tr><td> Hesperidin</td><td>—</td><td>+</td><td>—</td></tr><tr><td> Naringenin</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Naringin</td><td>—</td><td>+++</td><td>—</td></tr><tr><td> Neohesperidin</td><td>—</td><td>++</td><td>—</td></tr><tr><td>Flavones</td><td> </td><td> </td><td> </td></tr><tr><td> Apigenin</td><td>—</td><td>++</td><td>—</td></tr><tr><td> Baicalein</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Luteolin</td><td>++++</td><td>++++</td><td>++</td></tr><tr><td> Tangeretin</td><td>++</td><td>—</td><td>—</td></tr><tr><td> Wogonin</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Aurones</td><td> </td><td> </td><td> </td></tr><tr><td> Sulfuretin</td><td>—</td><td>++</td><td>—</td></tr><tr><td>Dihydrochalcones</td><td> </td><td> </td><td> </td></tr><tr><td> Phloretin</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Flavonols</td><td> </td><td> </td><td> </td></tr><tr><td> Silybin</td><td>++++</td><td>—</td><td>+</td></tr><tr><td>Chalcones</td><td> </td><td> </td><td> </td></tr><tr><td> Cardamonin</td><td>+</td><td>++</td><td>—</td></tr><tr><td>Isoflavones</td><td> </td><td> </td><td> </td></tr><tr><td> Calycosin</td><td>+++</td><td>++++</td><td>+++</td></tr><tr><td> Calycosin-7-O-glc</td><td>+++</td><td>++</td><td>—</td></tr><tr><td> Daidzein</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Formononetin</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Genistein</td><td>++++</td><td>++++</td><td>++</td></tr><tr><td> Genistin</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Puerarin</td><td>+</td><td>+++</td><td>—</td></tr><tr><td>Flavones</td><td> </td><td> </td><td> </td></tr><tr><td> (−)-Catechin</td><td>—</td><td>—</td><td>+</td></tr><tr><td> (−)-Epicatechin</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Flavonols</td><td> </td><td> </td><td> </td></tr><tr><td> Fisetin</td><td>+++</td><td>—</td><td>+</td></tr><tr><td> Galangin</td><td>—</td><td>++</td><td>—</td></tr><tr><td> Hyperin</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Icariin</td><td>—</td><td>—</td><td>+</td></tr><tr><td> Isorhamnetin</td><td>++++</td><td>++++</td><td>+++</td></tr><tr><td> Kaempferol</td><td>+</td><td>+</td><td>+</td></tr><tr><td> Quercetin</td><td>—</td><td>+</td><td>—</td></tr><tr><td> RNFG</td><td>—</td><td>++</td><td>—</td></tr><tr><td> 173-estradiol</td><td>++++</td><td>++++</td><td>+++</td></tr></table> |
f244a13738e3c1266d9bc518abe526108c6543937fdd0e769c2d47c39ae625ba.png | simple | <table><tr><td>Variables</td><td>N</td><td>Case/Control</td><td>OR(95%CI) <i>P</i><sub>h</sub><i>P</i></td><td>OR(95%CI) <i>P</i><sub>h</sub><i>P</i></td><td>OR(95%CI) <i>P</i><sub>h</sub><i>P</i></td><td>OR(95%CI) <i>P</i><sub>h</sub><i>P</i></td><td>OR(95%CI) <i>P</i><sub>h</sub><i>P</i></td></tr><tr><td></td><td></td><td></td><td>M-allele vs. W-allele</td><td>MW vs. WW</td><td>MM vs. WW</td><td>MM+MW vs. WW</td><td>MM vs. MW+WW</td></tr><tr><td>rs3740199</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total</td><td>5</td><td>1405/2531</td><td>1.02(0.93-1.12)0.538 0.726</td><td>1.03(0.87-1.21)0.811 0.743</td><td>1.03(0.85-1.25)0.527 0.758</td><td>1.03(0.88-1.20)0.631 0.714</td><td>1.00(0.86-1.17)0.630 0.967</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Asian</td><td>4</td><td>1242/2316</td><td>1.02(0.92-1.13)0.379 0.709</td><td>1.03(0.88-1.22)0.680 0.703</td><td>1.04(0.85-1.27)0.370 0.722</td><td>1.03(0.88-1.21)0.473 0.679</td><td>1.00(0.84-1.19)0.461 0.989</td></tr><tr><td>Caucasian</td><td>1</td><td>163/215</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Source of control</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HB</td><td>3</td><td>517/579</td><td>1.03(0.87-1.21)0.213 0.771</td><td>1.03(0.77-1.38)0.470 0.829</td><td>1.05(0.75-1.48)0.209 0.764</td><td>1.04(0.79-1.36)0.285 0.792</td><td>0.99(0.75-1.31)0.277 0.944</td></tr><tr><td>PB</td><td>2</td><td>888/1952</td><td>1.01(0.90-1.14)0.914 0.822</td><td>1.03(0.84-1.24)0.780 0.802</td><td>1.02(0.81-1.29)0.849 0.868</td><td>1.03(0.85-1.23)0.805 0.791</td><td>1.01(0.83-1.22)0.973 0.922</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>3</td><td>264/993</td><td>1.49(0.95-2.34)0.053 0.086</td><td>1.44(1.02-2.04)0.906 0.040</td><td>2.09(0.82-5.33)0.066 0.122</td><td>1.46(1.05-2.03)0.420 0.025</td><td>1.60(0.76-3.39)0.034 0.220</td></tr><tr><td>Female</td><td>3</td><td>824/1159</td><td>0.96(0.84-1.09)0.554 0.531</td><td>0.91(0.73-1.13)0.574 0.389</td><td>0.94(0.72-1.23)0.537 0.648</td><td>0.92(0.75-1.13)0.516 0.417</td><td>0.98(0.79-1.21)0.637 0.836</td></tr><tr><td>rs1278279</td><td>2</td><td>316/379</td><td>1.08(0.84-1.38)0.964 0.543</td><td>1.26(0.91-1.73)0.935 0.158</td><td>0.88(0.47-1.62)0.995 0.671</td><td>1.19(0.88-1.61)0.950 0.265</td><td>0.80(0.44-1.47)0.995 0.474</td></tr><tr><td>rs1871054</td><td>2</td><td>316/379</td><td>1.85(1.49-2.30)0.984 <0.001</td><td>1.12(0.75-1.67)0.824 0.592</td><td>2.81(1.84-4.27)0.964 <0.001</td><td>1.68(1.16-2.43)0.887 0.006</td><td>2.61(1.89-3.60)0.897 <0.001</td></tr><tr><td>rs1044122</td><td>2</td><td>316/379</td><td>0.95(0.77-1.18)0.838 0.665</td><td>1.05(0.75-1.48)0.978 0.759</td><td>0.87(0.55-1.37)0.803 0.543</td><td>1.01(0.73-1.39)0.948 0.972</td><td>0.84(0.56-1.26)0.767 0.394</td></tr></table> |
03bf356684fc6577f87dd54f05604ddf03a414b3c8bddaf93f846e4bf2b228d9.png | simple | <table><tr><td>Gene ID</td><td>ENSEMBL Gene ID</td><td>Gene name</td><td>Base Mean</td><td>Fold Change (log2)</td><td>p-adj</td></tr><tr><td>VIM</td><td>ENSECAG00000004216</td><td>vimentin</td><td>101,873.95</td><td>0.49</td><td>0.0846</td></tr><tr><td>LUM</td><td>ENSECAG00000018248</td><td>lumican</td><td>93,834.08</td><td>1.21</td><td>0.0000</td></tr><tr><td>EEF1A1</td><td>ENSECAG00000020363</td><td>eukaryotic translation elongation factor 1 alpha 1</td><td>80,865.77</td><td>0.35</td><td>0.4978</td></tr><tr><td>FN1</td><td>ENSECAG00000000701</td><td>fibronectin 1</td><td>76,204.43</td><td>− 0.03</td><td>0.9131</td></tr><tr><td>COL3A1</td><td>ENSECAG00000024769</td><td>collagen type III alpha 1</td><td>71,782.03</td><td>−0.28</td><td>0.3120</td></tr><tr><td>COL1A2</td><td>ENSECAG00000024740</td><td>collagen type I alpha 2</td><td>68,527.63</td><td>0.03</td><td>0.9444</td></tr><tr><td>ACTG1</td><td>ENSECAG00000018600</td><td>actin gamma 1</td><td>67,827.73</td><td>0.59</td><td>0.1648</td></tr><tr><td>DCN</td><td>ENSECAG00000020413</td><td>decorin</td><td>66,957.05</td><td>0.72</td><td>0.0000</td></tr><tr><td>CLU</td><td>ENSECAG00000007010</td><td>clusterin</td><td>60,592.80</td><td>0.54</td><td>0.3689</td></tr><tr><td>CTSK</td><td>ENSECAG00000019087</td><td>cathepsin K</td><td>50,743.84</td><td>−0.01</td><td>0.9822</td></tr><tr><td>PSAP</td><td>ENSECAG00000021672</td><td>prosaposin</td><td>42,671.36</td><td>−0.71</td><td>0.0123</td></tr><tr><td>COL6A3</td><td>ENSECAG00000020887</td><td>collagen type VI alpha 3 chain</td><td>39,357.71</td><td>−0.81</td><td>0.0000</td></tr><tr><td>AHNAK</td><td>ENSECAG00000014229</td><td>AHNAK nucleoprotein</td><td>32,777.16</td><td>−1.03</td><td>0.0004</td></tr><tr><td>TPT1</td><td>ENSECAG00000018348</td><td>tumor protein, translationally-controlled 1</td><td>32,069.02</td><td>0.86</td><td>0.0000</td></tr><tr><td>RPL4</td><td>ENSECAG00000023179</td><td>ribosomal protein L4</td><td>28,412.14</td><td>0.55</td><td>0.0555</td></tr><tr><td>ANXA1</td><td>ENSECAG00000015794</td><td>annexin A1</td><td>28,358.48</td><td>1.22</td><td>0.0000</td></tr><tr><td>HSP90AA1</td><td>ENSECAG00000018948</td><td>heat shock protein 90 alpha family class A member 1</td><td>27,249.39</td><td>0.36</td><td>0.5410</td></tr><tr><td>ASPN</td><td>ENSECAG00000007047</td><td>asporin</td><td>27,102.67</td><td>1.44</td><td>0.0000</td></tr><tr><td>EIF4G2</td><td>ENSECAG00000014700</td><td>eukaryotic translation initiation factor 4 gamma 2</td><td>25,563.63</td><td>1.26</td><td>0.0000</td></tr><tr><td>HSPA8</td><td>ENSECAG00000013510</td><td>heat shock protein family A (Hsp70) member 8</td><td>23,372.98</td><td>−0.02</td><td>0.9496</td></tr><tr><td>HTRA1</td><td>ENSECAG00000009990</td><td>HtrA serine peptidase 1</td><td>23,322.81</td><td>−0.18</td><td>0.7559</td></tr><tr><td>APP</td><td>ENSECAG00000021011</td><td>amyloid beta precursor protein</td><td>21,959.94</td><td>−0.08</td><td>0.7687</td></tr><tr><td>CLTC</td><td>ENSECAG00000019077</td><td>clathrin heavy chain</td><td>21,758.80</td><td>0.44</td><td>0.1597</td></tr><tr><td>CTNNB1</td><td>ENSECAG00000006949</td><td>catenin beta 1</td><td>21,082.51</td><td>0.57</td><td>0.0512</td></tr><tr><td>FAP</td><td>ENSECAG00000011790</td><td>fibroblast activation protein alpha</td><td>20,454.17</td><td>1.72</td><td>0.0000</td></tr></table> |
579b4bef306c94fe2dcdd892ef0dbeefffe606a648610e055e400e7204f6f632.png | simple | <table><tr><td>Treatment category</td><td></td></tr><tr><td>Cat I</td><td>Treatment for new patients with first-line anti-TB drugs (2 months of INH, RIF, EMB, PZA/4 months of INH, RIF)</td></tr><tr><td>Cat II</td><td>Re-treatment regimen with first-line anti-TB drugs (2 months of STR, INH, RIF, EMB, PZA/1 month of INH, RIF, EMB, PZA/3 months of INH, RIF, EMB)</td></tr><tr><td>New</td><td>A patient who has never had treatment for TB or who has taken anti-TB drugs for <1 month</td></tr><tr><td>Close contact</td><td>Close contacts of MDR-TB patients who develop active TB</td></tr><tr><td>Failure</td><td>A patient previously treated for TB who is started on a re-treatment regimen after previous treatment has failed</td></tr><tr><td>Relapse</td><td>A patient who was previously declared cured or treatment completed and is diagnosed with bacteriologically-positive (sputum smear or culture) TB</td></tr><tr><td>Standard MDR-TB regimen</td><td>6 months of AMK, PZA, LFX, ETH, DCS/18 months of PZA, LFX, ETH, DCS a</td></tr></table> |
eb1f9d0a9fd94eddcc87ac5bb123c4fbe16e06f0346ec6fe81b6e6048ef544e3.png | complex | <table><tr><td> </td><td> </td><td>PT (n = 21)</td><td>ST (n = 23)</td><td>p value</td></tr><tr><td rowspan="3">Global score</td><td>Baseline</td><td>26.0 ± 11.2</td><td>29.7 ± 9.8</td><td>0.256<sup>†</sup></td></tr><tr><td>After training</td><td>25.7 ± 10.6</td><td>24.5 ± 7.7</td><td>0.678<sup>†</sup></td></tr><tr><td>Follow-up</td><td>23.9 ± 10,0</td><td>21.8 ± 8.1</td><td>0.465<sup>†</sup></td></tr><tr><td rowspan="3">Pain</td><td>Baseline</td><td>46.2 ± 19.3</td><td>50.2 ± 23.3</td><td>0.538<sup>†</sup></td></tr><tr><td>After training</td><td>41.2 ± 23.6</td><td>35.7 ± 22.0</td><td>0.425<sup>†</sup></td></tr><tr><td>Follow-up</td><td>38.8 ± 23.3</td><td>29.6 ± 24.0</td><td>0.203<sup>†</sup></td></tr><tr><td rowspan="3">Physical function</td><td>Baseline</td><td>16.2 ± 10.2</td><td>20.1 ± 10.4</td><td>0.210<sup>†</sup></td></tr><tr><td>After training</td><td>14.0 ± 9.7</td><td>13.8 ± 8.1</td><td>0.943<sup>†</sup></td></tr><tr><td>Follow-up</td><td>12.8 ± 8.4</td><td>10.9 ± 6.2</td><td>0.382<sup>†</sup></td></tr><tr><td rowspan="3">Social function</td><td>Baseline</td><td>18.4 ± 15.2</td><td>20.3 ± 11.3</td><td>0.625<sup>†</sup></td></tr><tr><td>After training</td><td>16.3 ± 12.8</td><td>16.0 ± 10.1</td><td>0.924<sup>†</sup></td></tr><tr><td>Follow-up</td><td>17.7 ± 12.9</td><td>17.1 ± 10.4</td><td>0.864<sup>†</sup></td></tr><tr><td rowspan="3">Health perception</td><td>Baseline</td><td>50.0 ± 19.0</td><td>57.6 ± 15.5</td><td>0.151<sup>†</sup></td></tr><tr><td>After training</td><td>49.2 ± 21.1</td><td>47.5 ± 11.6</td><td>0.743<sup>†</sup></td></tr><tr><td>Follow-up</td><td>44.4 ± 15.2</td><td>49.3 ± 17.4</td><td>0.334<sup>†</sup></td></tr><tr><td rowspan="2">Mental function</td><td>Baseline</td><td>31.5 ± 11.6</td><td>34,3 ± 12.0</td><td>0.434<sup>†</sup></td></tr><tr><td>After training</td><td>38.8 ± 9.3</td><td>37.7 ± 7.7</td><td>0.678<sup>†</sup></td></tr><tr><td> </td><td>Follow-up</td><td>34.4 ± 10.3</td><td>32.9 ± 11.6</td><td>0.645<sup>†</sup></td></tr></table> |
b6c956023a70bd9e5bef7aa234cb2623bfe85b79ebfcc90918bc16c12d636018.png | complex | <table><tr><td>Contact Stress, GPa</td><td>Rolling Time, h</td><td>Rolling Speed, rpm</td><td>Condition</td></tr><tr><td>2.5</td><td rowspan="2">12, 24</td><td rowspan="2">1000</td><td rowspan="2">dry</td></tr><tr><td>3.0</td></tr></table> |
577423bcffe69e61a528803a48e1b2c5478bf31124800088f002b17dd4f37a4d.png | simple | <table><tr><td>Effect size</td><td>Point estimatefreqpost mean post median</td><td>Percentile bootstrap</td><td>Bias-corrected bootstrap</td><td>Bayesian equal-tail credibilityintervals</td><td>Bayesian HPD credibilityintervals</td></tr><tr><td>Med<sub>ps</sub></td><td>0.1080.1050.106</td><td>[0.059, 0.183]</td><td>[0.046, 0.161]</td><td>[0.054, 0.154]</td><td>[0.052, 0.151]</td></tr><tr><td>Proportion</td><td>0.4110.4120.378</td><td>[0.193, 1.055]</td><td>[0.190, 0.950]</td><td>[0.163, 0.853]</td><td>[0.153, 0.734]</td></tr><tr><td>Ratio</td><td>0.697−0.5260.598</td><td>[−1.986, 4.915]</td><td>[0.137, 5.213]</td><td>[0.186, 3.308]</td><td>[0.133, 2.484]</td></tr></table> |
c19abd2abfd3ff265a1c085257fed604b47910c81521337bfc56b64a61814b78.png | complex | <table><tr><td rowspan="2" colspan="2">Segmental LV wall</td><td colspan="3">Endocardial (%)</td><td colspan="3">Middle (%)</td><td colspan="3">Epicardial (%)</td></tr><tr><td>Preoperative</td><td>Postoperative</td><td><i>P</i>-value</td><td>Preoperative</td><td>Postoperative</td><td><i>P</i>-value</td><td>Preoperative</td><td>Postoperative</td><td><i>P</i>-value</td></tr><tr><td rowspan="2">Apical 4-CH view</td><td>Lateral</td><td>−15.38 ± 7.90</td><td>−8.55 ± 6.58</td><td><0.001</td><td>−12.64 ± 6.77</td><td>−6.70 ± 5.42</td><td><0.001</td><td>−10.61 ± 5.99</td><td>−5.32 ± 4.62</td><td><0.001</td></tr><tr><td>Septum</td><td>−13.95 ± 7.32</td><td>−10.77 ± 7.19</td><td>0.026</td><td>−11.27 ± 6.15</td><td>−9.01 ± 6.08</td><td>0.054</td><td>−9.25 ± 5.33</td><td>−7.71 ± 5.29</td><td>0.119</td></tr><tr><td rowspan="2">Apical 3-CH view</td><td>Anteroseptum</td><td>−15.75 ± 7.72</td><td>−8.03 ± 7.10</td><td><0.001</td><td>−12.28 ± 6.28</td><td>−6.35 ± 5.89</td><td><0.001</td><td>−9.65 ± 5.26</td><td>−5.13 ± 5.00</td><td><0.001</td></tr><tr><td>Posterior</td><td>−17.33 ± 6.88</td><td>−10.97 ± 8.21</td><td><0.001</td><td>−14.01 ± 6.05</td><td>−8.84 ± 6.87</td><td><0.001</td><td>−11.46 ± 5.44</td><td>−7.21 ± 5.88</td><td>0.001</td></tr><tr><td rowspan="2">Apical 2-CH view</td><td>Anterior</td><td>−15.49 ± 7.07</td><td>−7.51 ± 7.46</td><td><0.001</td><td>−12.55 ± 6.42</td><td>−5.85 ± 6.16</td><td><0.001</td><td>−10.31 ± 5.96</td><td>−4.64 ± 5.20</td><td><0.001</td></tr><tr><td>Inferior</td><td>−17.34 ± 7.38</td><td>−12.90 ± 8.69</td><td>0.009</td><td>−13.89 ± 6.26</td><td>−10.40 ± 7.22</td><td>0.013</td><td>−11.18 ± 5.44</td><td>−8.49 ± 6.15</td><td>0.020</td></tr></table> |
b45eaddb81098559714d0e9c59b4e87a1070b1c140bea0768bb9a2d3a373e3f4.png | simple | <table><tr><td></td><td>Screening</td><td>Randomization</td><td>3 monthlyFU</td><td>6 monthlyFU</td><td>End of study</td></tr><tr><td>25(OH)D3 serum levels</td><td></td><td>X</td><td>X(when 25(OH)D3 levels >80 ng/ml and study drug temporarily interrupted)</td><td>X</td><td></td></tr><tr><td>Blood sample for DNA analysis</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>Hemoglobin, Hematocrit</td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>WBC count and differentiation</td><td>X</td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>RBC count</td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>Platelet count</td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>Renal function (creatinine)</td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>Liver function (AF, ALT, gamma-GT, LDH)</td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>Serum calcium</td><td>X</td><td></td><td>X</td><td></td><td>X</td></tr><tr><td>Serum phosphate</td><td>X</td><td></td><td>X</td><td></td><td>X</td></tr><tr><td>Albumin</td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>24 h urine calcium</td><td></td><td></td><td></td><td></td><td>X</td></tr></table> |
6bc4078bb568e579a62fcaf19f47a15c93d6bf8e74d5ad57c652b4102db75973.png | simple | <table><tr><td>Author, date</td><td>No. Participants = n</td><td>Avg age at start</td><td>Cast changed</td><td>Avg days in casts - ‘fast’ group</td><td>Tenotomy rate</td><td>Follow up</td><td>Comment</td></tr><tr><td>Morecuende, 2005</td><td>230(non-random)</td><td>Not stated</td><td>5 days</td><td>30</td><td>85%</td><td>Study ran over 11 years</td><td>Older study, NR sample</td></tr><tr><td>Harnett, 2011</td><td>40(RCT)</td><td>21 days</td><td>3 / week</td><td>16</td><td>79%</td><td>Min 6 mthsAve 8 mths</td><td>Youngest children</td></tr><tr><td>Xu, 2011</td><td>26(RCT)</td><td>92 days</td><td>2 / week</td><td>20.6</td><td>87%</td><td>2–6 years</td><td><i>Manipulation time of 2 min</i></td></tr><tr><td>Ullah, 2014</td><td>28(RCT)</td><td>18 weeks</td><td>2 / week</td><td>23.3</td><td>80%</td><td>Not reported</td><td></td></tr><tr><td>Elgohary, 2015</td><td>41(RCT)</td><td>11 weeks (SD 7)</td><td>2 / week</td><td>18.1 (SD 3)</td><td>91%</td><td>12–48 mths</td><td>Relapse rate 15% both groups</td></tr><tr><td>RCT data summary</td><td>RCTs<i>n</i> = 135</td><td>11 weeks</td><td>2/week</td><td>19.5 days</td><td>84% average</td><td>1 year(3 RCTs)</td><td>Young infants, 2 min. Stretch</td></tr></table> |
5d239577ca52c29740b32cbe741ce8b0d43c78b8dc8f05061d2aa350360b93de.png | simple | <table><tr><td>Variable</td><td>Coefficient</td><td>S.E.</td><td>p-value</td><td>OR</td><td>95%CI</td></tr><tr><td>Intercept</td><td>-5.21</td><td>4.44</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Mains water to the farmhouse</td><td>-8.56</td><td>1.25</td><td>< 0.0001</td><td>0.0002</td><td>1.64E<sup>-5 </sup>: 2.22E<sup>-3</sup></td></tr><tr><td>Number of positive samples</td><td>0.30</td><td>0.07</td><td>0.0002</td><td>1.36</td><td>1.19 : 1.56</td></tr><tr><td>Y coordinate (1 km)</td><td>0.014</td><td>0.006</td><td>0.026</td><td>1.014</td><td>1.0027 : 1.026</td></tr></table> |
1b4d543aa8f5609d7a0b6a6c86ab39ee3ec600b02765af9d34548cb7cd7a4dbf.png | complex | <table><tr><td></td><td colspan="3">Bacteria</td><td colspan="3">Methanogens</td></tr><tr><td>Community</td><td>Similarity</td><td>Pseudo- <i>F</i></td><td><i>P-</i>value</td><td>Similarity</td><td>Pseudo- <i>F</i></td><td><i>P-</i>value</td></tr><tr><td>Treatment effect</td><td></td><td>4.54</td><td>0.007</td><td></td><td>9.06</td><td>0.003</td></tr><tr><td colspan="7">Pairwise comparisons</td></tr><tr><td> CON versus CHI</td><td>59.5</td><td>2.33</td><td>0.046</td><td>76.0</td><td>1.09</td><td>0.360</td></tr><tr><td> CON versus IVY</td><td>73.9</td><td>1.62</td><td>0.118</td><td>62.4</td><td>3.10</td><td>0.024</td></tr><tr><td> CHI versus IVY</td><td>60.1</td><td>2.17</td><td>0.048</td><td>60.7</td><td>7.00</td><td>0.003</td></tr></table> |
58ff983adbc67fe6ad39e756680513b34cd2b3745028b306eb975b11407583a0.png | simple | <table><tr><td>Code Level 3</td><td>Label level 3</td><td>Assigned land use type</td></tr><tr><td>111</td><td>Continuous urban fabric</td><td>Urban</td></tr><tr><td>112</td><td>Discontinuous urban fabric</td><td>Urban</td></tr><tr><td>121</td><td>Industrial or commercial units</td><td>Urban</td></tr><tr><td>122</td><td>Road and rail networks and associated land</td><td>Urban</td></tr><tr><td>123</td><td>Port areas</td><td>Urban</td></tr><tr><td>124</td><td>Airports</td><td>Urban</td></tr><tr><td>131</td><td>Mineral extraction sites</td><td>Urban</td></tr><tr><td>132</td><td>Dump sites</td><td>Urban</td></tr><tr><td>133</td><td>Construction sites</td><td>Urban</td></tr><tr><td>141</td><td>Green urban areas</td><td>Urban</td></tr><tr><td>142</td><td>Sport and leisure facilities</td><td>Urban</td></tr><tr><td>211</td><td>Non-irrigated arable land</td><td>Arable</td></tr><tr><td>212</td><td>Permanently irrigated land</td><td>Arable</td></tr><tr><td>213</td><td>Rice fields</td><td>Arable</td></tr><tr><td>221</td><td>Vineyards</td><td>Arable</td></tr><tr><td>222</td><td>Fruit trees and berry plantations</td><td>Arable</td></tr><tr><td>223</td><td>Olive groves</td><td>Arable</td></tr><tr><td>231</td><td>Pastures</td><td>Grassland</td></tr><tr><td>241</td><td>Annual crops associated with permanent crops</td><td>Arable</td></tr><tr><td>242</td><td>Complex cultivation patterns</td><td>Arable</td></tr><tr><td>243</td><td>Land principally occupied by agriculture, with significant areas of natural vegetation</td><td>Grassland</td></tr><tr><td>244</td><td>Agro-forestry areas</td><td>Forest</td></tr><tr><td>311</td><td>Broad-leaved forest</td><td>Forest</td></tr><tr><td>312</td><td>Coniferous forest</td><td>Forest</td></tr><tr><td>313</td><td>Mixed forest</td><td>Forest</td></tr><tr><td>321</td><td>Natural grasslands</td><td>Grassland</td></tr><tr><td>322</td><td>Moors and heathland</td><td>Grassland</td></tr><tr><td>323</td><td>Sclerophyllous vegetation</td><td>Grassland</td></tr><tr><td>324</td><td>Transitional woodland-shrub</td><td>Forest</td></tr><tr><td>333</td><td>Sparsely vegetated areas</td><td>Grassland</td></tr></table> |
b1c4c1ca3a7dc812da54a86e8bf40c24687b53b53274b40f1e83741b64b586c5.png | simple | <table><tr><td>Variables</td><td>Crude ORs</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Older Ages: Age ≥ 80</td><td>1.74 (1.28, 2.36) *</td><td>1.29 (0.93, 1.80)</td><td></td><td>1.26 (0.91, 1.75)</td></tr><tr><td>Living Alone</td><td>1.66 (1.26, 2.19) *</td><td>1.27 (0.91, 1.78)</td><td></td><td>1.31 (0.93, 1.85)</td></tr><tr><td>Low Education</td><td>1.94 (1.49, 2.51) *</td><td>1.63 (1.24, 2.16) *</td><td></td><td>1.60 (1.21, 2.12) *</td></tr><tr><td>Not Married</td><td>1.67 (1.34, 2.09) *</td><td>1.28 (0.95, 1.72)</td><td></td><td>1.24 (0.92, 1.67)</td></tr><tr><td>Male</td><td>0.82 (0.66, 1.02)</td><td>1.11 (0.85, 1.46)</td><td></td><td>1.13 (0.86, 1.48)</td></tr><tr><td>Pct. Residential</td><td>1.01 (1.00, 1.02) *</td><td></td><td>1.01 (1.00, 1.02) *</td><td>1.01 (1.00, 1.02) *</td></tr><tr><td>Pct. Vegetation</td><td>1.00 (0.998, 1.01)</td><td></td><td>1.00 (0.996, 1.01)</td><td>1.00 (0.995, 1.01)</td></tr><tr><td>Avg Build Height</td><td>1.00 (0.99, 1.00)</td><td></td><td>0.98 (0.96, 0.99) *</td><td>0.98 (0.96, 0.99) *</td></tr><tr><td>Std Build Height</td><td>1.01 (0.999, 1.02)</td><td></td><td>1.03 (1.01, 1.04) *</td><td>1.03 (1.01, 1.04) *</td></tr></table> |
759f138e626de5d09726e5aa71a7e9cb0a73d9631fe755793c11dee09c1a6be6.png | simple | <table><tr><td><i>Function</i></td><td><i>P-value</i></td><td><i>No. of Genes</i></td></tr><tr><td>Cellular movement</td><td>2.10E-35 to 3.60E-05</td><td>584</td></tr><tr><td>Cell death</td><td>1.99E-30 to 3.56E-05</td><td>853</td></tr><tr><td>Cellular development</td><td>2.08E-29 to 3.43E-05</td><td>730</td></tr><tr><td>Cellular growth and proliferation</td><td>3.01E-28 to 2.40E-05</td><td>912</td></tr><tr><td>Cellular assembly and organization</td><td>1.24E-15 to 3.32E-05</td><td>460</td></tr></table> |
1e7acbb1731e2adf341b4bd00b4aa549b184ca1ae4ff3395ed982ea25e06ba92.png | simple | <table><tr><td>Food Groups</td><td>Factor I Meat–Instant Food Dietary Pattern</td><td>Factor II Vege–Seafood Dietary Pattern</td><td>Factor III Cereal–Dairy Dietary Pattern</td></tr><tr><td>Milk</td><td>−0.174</td><td>0.047</td><td>0.597</td></tr><tr><td>Dairy products</td><td>0.038</td><td>0.058</td><td>0.634</td></tr><tr><td>Eggs</td><td>0.471</td><td>0.131</td><td>0.154</td></tr><tr><td>Meat</td><td>0.552</td><td>0.265</td><td>−0.037</td></tr><tr><td>Organ meats</td><td>0.313</td><td>0.127</td><td>0.036</td></tr><tr><td>Legumes/soy products</td><td>0.331</td><td>0.354</td><td>0.146</td></tr><tr><td>Seafood</td><td>0.312</td><td>0.400</td><td>0.070</td></tr><tr><td>Light-colored vegetables</td><td>−0.055</td><td>0.815</td><td>0.078</td></tr><tr><td>Dark-colored vegetables</td><td>−0.084</td><td>0.841</td><td>0.080</td></tr><tr><td>Fruit</td><td>−0.063</td><td>0.440</td><td>0.355</td></tr><tr><td>Vegetables with oil/dressing</td><td>0.278</td><td>0.569</td><td>−0.053</td></tr><tr><td>Rice/flour products</td><td>0.295</td><td>−0.011</td><td>0.521</td></tr><tr><td>Whole grains</td><td>−0.039</td><td>0.089</td><td>0.441</td></tr><tr><td>Root crops</td><td>0.126</td><td>0.241</td><td>0.397</td></tr><tr><td>Refined dessert</td><td>0.327</td><td>0.226</td><td>−0.079</td></tr><tr><td>Jam/honey</td><td>0.317</td><td>−0.066</td><td>0.453</td></tr><tr><td>Sugary drinks</td><td>0.524</td><td>−0.173</td><td>0.154</td></tr><tr><td>Rice/flour cooked in oil</td><td>0.405</td><td>0.011</td><td>0.238</td></tr><tr><td>Deep-fried food</td><td>0.674</td><td>0.111</td><td>−0.030</td></tr><tr><td>Instant noodle</td><td>0.397</td><td>−0.115</td><td>−0.009</td></tr><tr><td>Processed food</td><td>0.611</td><td>0.051</td><td>0.053</td></tr><tr><td>Sauce</td><td>0.549</td><td>0.076</td><td>−0.035</td></tr></table> |
e1fa0426ea424643bbf84610bbceba4030cf407823b52df73b07bc80fc73ab92.png | complex | <table><tr><td rowspan="2">Algorithm</td><td rowspan="2">TP (%)</td><td rowspan="2">FN (%)</td><td rowspan="2">FP (%)</td><td rowspan="2">SE (%)</td><td rowspan="2">+P (%)</td><td colspan="3">Threshold values</td></tr><tr><td>THR<sub>1</sub></td><td>THR<sub>2</sub></td><td>THR<sub>3</sub></td></tr><tr><td>Proposed</td><td rowspan="2">100</td><td rowspan="2">0.32</td><td rowspan="2">0</td><td rowspan="2">99.78</td><td rowspan="2">100</td><td rowspan="2"><i>M</i><i>A</i><sub>beat</sub>+<i>α</i></td><td rowspan="2"><i>W</i><sub>2</sub></td><td rowspan="2">NA</td></tr><tr><td>algorithm</td></tr><tr><td>AF1</td><td>69.5</td><td>7.5</td><td>30.5</td><td>90.25</td><td>69.5</td><td>0.31</td><td>0.0001</td><td>-0.001</td></tr><tr><td>AF2</td><td>0.018</td><td>0.27</td><td>99.98</td><td>6.25</td><td>0.018</td><td>0.21</td><td>0.75</td><td>NA</td></tr><tr><td>AF3</td><td>0</td><td>0</td><td>100</td><td>NaN</td><td>0</td><td>62</td><td>NA</td><td>NA</td></tr><tr><td>FD1</td><td>0.27</td><td>2.8</td><td>99.73</td><td>8.79</td><td>0.27</td><td>0.099</td><td>NA</td><td>NA</td></tr><tr><td>FD2</td><td>0</td><td>0</td><td>100</td><td>NaN</td><td>0</td><td>150</td><td>NA</td><td>NA</td></tr><tr><td>DF1</td><td>0</td><td>0</td><td>100</td><td>NaN</td><td>0</td><td>21</td><td>NA</td><td>NA</td></tr><tr><td>DF2</td><td>48.8</td><td>14.2</td><td>51.2</td><td>77.46</td><td>48.8</td><td>1</td><td>0.06</td><td>NA</td></tr><tr><td>FS1</td><td>2.42</td><td>0.3</td><td>97.58</td><td>88.97</td><td>2.42</td><td>154.5</td><td>NA</td><td>NA</td></tr><tr><td>FS2</td><td>42.46</td><td>6.9</td><td>57.54</td><td>86.02</td><td>42.46</td><td>0.55</td><td>0.47</td><td>NA</td></tr></table> |
d722f7edce3ef4b88381cfaca3b7b6c41098530209783c41c5a14e1f8d0f0f38.png | simple | <table><tr><td></td><td>Cases</td><td>sCD157 <31.02 ng/ml</td><td>sCD157 ≥31.02 ng/ml</td><td><i>P</i> value<sup>*</sup></td></tr><tr><td>MPM, <i>n</i></td><td>61</td><td>30</td><td>31</td><td></td></tr><tr><td>Age at diagnosis, y</td><td></td><td></td><td></td><td>0.062</td></tr><tr><td> mean ± SD</td><td></td><td>73.07 ± 10,46</td><td>77.39 ± 6.76</td><td></td></tr><tr><td> median (range)</td><td></td><td>73.50 (52–94)</td><td>79.00 (61–89)</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td>0.106</td></tr><tr><td> Male</td><td>40</td><td>23</td><td>17</td><td></td></tr><tr><td> Female</td><td>21</td><td>7</td><td>14</td><td></td></tr><tr><td>Histologic subtype</td><td></td><td></td><td></td><td>0.951</td></tr><tr><td> Epithelioid</td><td>47</td><td>23</td><td>24</td><td></td></tr><tr><td> Sarcomatoid</td><td>5</td><td>3</td><td>2</td><td></td></tr><tr><td> Biphasic</td><td>2</td><td>1</td><td>1</td><td></td></tr><tr><td> NOS<sup>a</sup></td><td>7</td><td>3</td><td>4</td><td></td></tr><tr><td>Cytology</td><td></td><td></td><td></td><td>0.359</td></tr><tr><td> negative</td><td>21</td><td>13</td><td>8</td><td></td></tr><tr><td> positive</td><td>21</td><td>9</td><td>12</td><td></td></tr><tr><td> suspicious</td><td>19</td><td>8</td><td>11</td><td></td></tr><tr><td>PMN<sup>b</sup> (<i>n</i> = 54)</td><td></td><td></td><td></td><td>0.516</td></tr><tr><td> <10 cells × 10 (HPF, 200×)<sup>c</sup></td><td>36</td><td>17</td><td>19</td><td></td></tr><tr><td> 10–50 cells × 1 (HPF, 200×)</td><td>14</td><td>8</td><td>6</td><td></td></tr><tr><td> >50 cells × 10 (HPF, 200×)</td><td>4</td><td>1</td><td>3</td><td></td></tr><tr><td>CD157 expression in biopsy tissues (<i>n</i> = 29)</td><td></td><td></td><td></td><td>0.06</td></tr><tr><td> H-score <110</td><td>11</td><td>8</td><td>3</td><td></td></tr><tr><td> H-score ≥110</td><td>18</td><td>6</td><td>12</td><td></td></tr><tr><td>Follow-up (<i>n</i> = 54)</td><td></td><td></td><td></td><td>0.005</td></tr><tr><td> DOD<sup>d</sup></td><td>43</td><td>17</td><td>26</td><td></td></tr><tr><td> AWD<sup>e</sup></td><td>11</td><td>10</td><td>1</td><td></td></tr></table> |
6a1cf9a23b9a956d1edaa89f6d2ff935f1a3a9393f3f1e54ddb026563b77a056.png | simple | <table><tr><td>Partition number</td><td>Cluster number</td><td>BRCA1</td><td>BRCA2</td><td>Number of genes selected</td></tr><tr><td>1</td><td>1</td><td>0</td><td>4</td><td>80</td></tr><tr><td></td><td>2</td><td>7</td><td>4</td><td></td></tr><tr><td>2</td><td>1</td><td>7</td><td>4</td><td>110</td></tr><tr><td></td><td>2</td><td>0</td><td>4</td><td></td></tr><tr><td>3</td><td>1</td><td>5</td><td>3</td><td>73</td></tr><tr><td></td><td>2</td><td>2</td><td>5</td><td></td></tr><tr><td>4</td><td>1</td><td>6</td><td>0</td><td>61</td></tr><tr><td></td><td>2</td><td>1</td><td>8</td><td></td></tr></table> |
7ece8b867bb765050e160706db5dc5a97ac65b2451d1fed44bd50bb921ea32b7.png | complex | <table><tr><td>miRNA name</td><td>PTC</td><td><i>N</i></td><td><i>P</i>‐value</td><td>Fold change</td></tr><tr><td colspan="5">Upregulated</td></tr><tr><td>miR‐221‐5p</td><td>10.35 ± 3.68</td><td>2.88 ± 1.15</td><td><0.001</td><td>3.91 ± 1.36</td></tr><tr><td>miR‐222‐5p</td><td>7.80 ± 1.18</td><td>3.44 ± 0.73</td><td><0.001</td><td>2.35 ± 0.52</td></tr><tr><td>miR‐34a‐5p</td><td>7.45 ± 1.22</td><td>2.21 ± 1.43</td><td><0.001</td><td>2.94 ± 0.74</td></tr><tr><td>miR‐146b‐5p</td><td>10.39 ± 2.97</td><td>1.7 ± 0.35</td><td><0.001</td><td>6.11 ± 1.02</td></tr><tr><td>miR‐21‐5p</td><td>8.03 ± 2.77</td><td>3.26 ± 0.67</td><td><0.001</td><td>2.53 ± 0.84</td></tr><tr><td>miR‐31‐5p</td><td>6.52 ± 0.98</td><td>2.93 ± 0.39</td><td><0.001</td><td>2.12 ± 0.47</td></tr><tr><td colspan="5">Downregulated</td></tr><tr><td>miR‐181‐5p</td><td>3.91 ± 1.32</td><td>7.40 ± 2.21</td><td><0.001</td><td>2.00 ± 0.51</td></tr><tr><td>miR‐138‐5p</td><td>4.00 ± 1.55</td><td>7.05 ± 1.99</td><td><0.001</td><td>1.76 ± 0.36</td></tr></table> |
ab6c1a3f6dd1099970c1375d9962fb4fecc214d6a6e3412966e44425bb1a2e14.png | complex | <table><tr><td> </td><td> </td><td colspan="2">Single methods</td><td colspan="2">Combined method</td></tr><tr><td>Case</td><td>Histology (Lauren)</td><td>IHC (Score)</td><td>SISH (≥ 2.0/< 2.0)</td><td>IHC (Score)</td><td>SISH (≥ 2.0/< 2.0)</td></tr><tr><td>6693</td><td>i</td><td>2+</td><td>≥2.0</td><td>3+</td><td>≥2.0</td></tr><tr><td>9924</td><td>i</td><td>2+</td><td><2.0</td><td>1+</td><td><2.0</td></tr><tr><td>20209</td><td>i</td><td>2+</td><td>≥2.0</td><td>3+</td><td>≥2.0</td></tr><tr><td>1057</td><td>d</td><td>3+</td><td><2.0</td><td>2+</td><td><2.0</td></tr></table> |
d5106327c9e794a372e1442bf19ff047dd865b186c7451a373f984fdcbfdffbd.png | simple | <table><tr><td></td><td>pN0 and pN1</td><td>pN2 and pN3</td><td>p-value</td></tr><tr><td>Percentage of positive tumors cells</td><td>47.12 +/- 29,.3</td><td>55.62 +/- 26.33</td><td>0.068</td></tr><tr><td>Staining intensity</td><td>1.22 +/- 0.82</td><td>1.43 +/- 0.75</td><td>0.036*</td></tr></table> |
2ed7ec51ddee38fffe932db400d99e888a461187fb08bb1477213521983e43b4.png | complex | <table><tr><td>Variables</td><td>Name and source of the original scales and items</td><td>α</td><td>Items (n)</td></tr><tr><td colspan="2">Socio-demographic factors<sup>a</sup></td><td></td><td>18</td></tr><tr><td colspan="4">Health behaviour</td></tr><tr><td> Physical activity</td><td>Health Questionnaire age 18–64 years [29]</td><td>–</td><td>1</td></tr><tr><td> Dietary habits</td><td>Food Frequency Questionnaire [30]</td><td>–</td><td>15</td></tr><tr><td> Smoking</td><td>Health Questionnaire age 18–64 years [7]</td><td>–</td><td>2</td></tr><tr><td> Alcohol consumption</td><td>AUDIT-C [31, 32]</td><td>–</td><td>3</td></tr><tr><td colspan="4">Health status</td></tr><tr><td> General health status</td><td>Survey in vocational schools in Bielefeld [36]</td><td>–</td><td>1</td></tr><tr><td> Diseases and complaints</td><td>Work Ability Index – Questionnaire [33]</td><td>–</td><td>6</td></tr><tr><td> Self-efficacy</td><td>Self-efficacy scale [24]</td><td>0.85</td><td>10</td></tr><tr><td> Irritation</td><td>Irritation scale [22]</td><td>0.88</td><td>8</td></tr><tr><td colspan="4">Occupational situation and prospects</td></tr><tr><td> Job satisfaction</td><td>COPSOQ: German standard version [23, 34]</td><td>0.81</td><td>7</td></tr><tr><td> Job strain and prospects</td><td>Additional questions (e.g., taking into account the current work situation, do you want to stay in this profession for the next five years?)</td><td>–</td><td>3</td></tr></table> |
ad64da938345c664ba760f7645ce1b64bf0fa316feae1ebdb38a22e752d55f9f.png | simple | <table><tr><td></td><td>Coefficient</td><td>Standard Error</td><td>P-value</td></tr><tr><td>HIV-infected</td><td></td><td></td><td></td></tr><tr><td><i>For Log IP-10</i></td><td></td><td></td><td></td></tr><tr><td>Gender</td><td>0.153</td><td>0.101</td><td>0.131</td></tr><tr><td>Age</td><td>0.005</td><td>0.005</td><td>0.250</td></tr><tr><td>Weight</td><td>0.002</td><td>0.003</td><td>0.554</td></tr><tr><td>Co-morbidity</td><td>-0.078</td><td>0.098</td><td>0.423</td></tr><tr><td><i>For log sCD14</i></td><td></td><td></td><td></td></tr><tr><td>Gender</td><td>0.074</td><td>0.056</td><td>0.196</td></tr><tr><td>Age</td><td>0.002</td><td>0.002</td><td>0.575</td></tr><tr><td>Weight</td><td>0.002</td><td>0.003</td><td>0.947</td></tr><tr><td>Co-morbidity</td><td>-0.003</td><td>0.055</td><td>0.963</td></tr><tr><td>HIV-uninfected</td><td></td><td></td><td></td></tr><tr><td><i>For Log IP-10</i></td><td></td><td></td><td></td></tr><tr><td>Gender</td><td>-0.098</td><td>0.148</td><td>0.508</td></tr><tr><td>Age</td><td>-0.007</td><td>0.008</td><td>0.318</td></tr><tr><td>Weight</td><td>0.005</td><td>0.009</td><td>0.594</td></tr><tr><td><i>For log sCD14</i></td><td></td><td></td><td></td></tr><tr><td>Gender</td><td>-0.074</td><td>0.057</td><td>0.196</td></tr><tr><td>Age</td><td>-0.001</td><td>0.002</td><td>0.575</td></tr><tr><td>Weight</td><td>0.001</td><td>0.003</td><td>0.947</td></tr></table> |
b8bca159ec31bc6bd1b1eae81e686b33000a96785167a6c01921ae8dcc97e795.png | complex | <table><tr><td>PROCEDURE</td><td colspan="3">ONCOLOGIC RESULTS</td></tr><tr><td>RARC<sup>*</sup></td><td>equivalent lymph node yields</td><td>comparable overall and recurrence-free survival</td><td>similar positive surgical margins in ≤ T2 disease</td></tr><tr><td>RAPN<sup>§</sup></td><td>comparable margin status</td><td colspan="2">equivalent local recurrence rates</td></tr><tr><td>RALNU<sup>#</sup></td><td colspan="3">studies with long-term follow-up are needed</td></tr></table> |
62ff4cfbefe39b414c04a56a971c531fbbabb20608106ea2578ecc6c6a4b7f3c.png | complex | <table><tr><td>Comorbidity</td><td colspan="2">ICD codes</td></tr><tr><td rowspan="2">Heart failure</td><td>ICD-8:</td><td>427, 428</td></tr><tr><td>ICD-10:</td><td>I42, I50, I110, J819</td></tr><tr><td rowspan="2">Ischaemic heart disease</td><td>ICD-8:</td><td>411, 412, 413, 414</td></tr><tr><td>ICD-10:</td><td>I20, I23, I24, I25,</td></tr><tr><td rowspan="2">Anemia</td><td>ICD-8:</td><td>280-285</td></tr><tr><td>ICD-10:</td><td>D60-D69</td></tr><tr><td rowspan="2">Cancer</td><td>ICD-8:</td><td>140-209</td></tr><tr><td>ICD-10:</td><td>C00-C97</td></tr><tr><td rowspan="2">Chronic obstructive pulmonary disease</td><td>ICD-8:</td><td>490, 491, 492</td></tr><tr><td>ICD-10:</td><td>J42, J44</td></tr><tr><td rowspan="2">Atrial fibrillation</td><td>ICD-8:</td><td>427.4</td></tr><tr><td>ICD-10:</td><td>I48</td></tr><tr><td rowspan="2">Acute myocardial infarction</td><td>ICD-8:</td><td>410</td></tr><tr><td>ICD-10:</td><td>I21, I22</td></tr><tr><td rowspan="2">Peripheral arterial disease</td><td>ICD-8:</td><td>443</td></tr><tr><td>ICD-10:</td><td>I70, I74</td></tr><tr><td rowspan="2">Diabetes</td><td>ICD-8:</td><td>250</td></tr><tr><td>ICD-10:</td><td>E10-E14</td></tr><tr><td rowspan="2">Hypertension</td><td>ICD-8:</td><td>400, 401</td></tr><tr><td>ICD-10:</td><td>I109, I119, !959, I270, I951</td></tr></table> |
83f7247e9fe57e12446d290b1544908826ba480a591d5575eeede8c4c3c29425.png | complex | <table><tr><td>Group Examined (ICD-9 Code)</td><td>0 μg Organic-Hg (%) (Reference Dose)</td><td>12.5 μg Organic-Hg (%)</td><td>25 μg Organic-Hg (%)</td><td>37.5 μg Organic-Hg (%)</td><td>Odds Ratio per μg Organic-Hg (95% CI) (<i>p</i>-value)</td></tr><tr><td>Febrile Seizure Cases (780.3)</td><td>218 (5.2)</td><td>60 (1.4)</td><td>3432 (81.5)</td><td>499 (11.9)</td><td rowspan="2">1 (0.993–1.003) (0.53)</td></tr><tr><td>Controls</td><td>2858 (3.4)</td><td>981 (1.1)</td><td>74,102 (87.1)</td><td>7,171 (8.4)</td></tr><tr><td>Failure to Thrive Cases (783.4)</td><td>322 (8.3)</td><td>106 (2.7)</td><td>3028 (77.6)</td><td>444 (11.4)</td><td rowspan="2">0.98 (0.97–0.98) (<0.001)</td></tr><tr><td>Controls</td><td>3270 (3.4)</td><td>1096 (1.2)</td><td>82,425 (86.5)</td><td>8458 (8.9)</td></tr><tr><td>Cerebral Degeneration Cases (330.xx or 331.xx)</td><td>92 (14.2)</td><td>13 (2.0)</td><td>483 (74.7)</td><td>59 (9.1)</td><td rowspan="2">0.95 (0.94–0.96) (<0.001)</td></tr><tr><td>Controls</td><td>5148 (3.8)</td><td>1558 (1.1)</td><td>116,038 (85.4)</td><td>13,145 (9.7)</td></tr></table> |
aea29679a7f78a0271bd9a0ee8e68c7027187d90f7adb27a687422dbc9bec239.png | simple | <table><tr><td>Advantages</td><td>Shortcomings</td></tr><tr><td>Available anywhere on the earth in any weather conditions for outdoor measurements at no cost</td><td>High cost of professional equipment</td></tr><tr><td>Tri-dimensional positioning with centimeter accuracy (Real Time Kinematics, RTK mode)</td><td>Not fully validated for gait analysis yet</td></tr><tr><td>No space restriction: freedom in the path selection, including uphill/downhill locomotion.</td><td>Limited time windows (2–4 h per day)</td></tr><tr><td>Free living conditions, i.e close to real life</td><td>One body segment measured only (head): Because of mandatory constant satellite access, the antenna must not be obstructed by body parts.</td></tr><tr><td>Unlimited number of consecutive strides: limited only by the memory capacity of the receiver and the duration of the batteries.</td><td>Outdoor analysis: difficult to standardize environmental conditions (weather, terrain).</td></tr><tr><td></td><td>Not fully miniaturized (cumbersome antenna).</td></tr></table> |
341d8314d66005f289ad2f64151b8d29628277bbc82d426f478893cb611471aa.png | complex | <table><tr><td colspan="4">Operation (Pipette-dependence mode<sup>a</sup>)</td><td>Purpose</td><td>Details</td></tr><tr><td rowspan="9">PF</td><td>1</td><td colspan="2">Input (I-mode)</td><td>Liquid charging into MMV wells</td><td>Figure 1c</td></tr><tr><td rowspan="2">2</td><td rowspan="2">Output (O-mode)</td><td>a. Transfer</td><td rowspan="2">Complete ejection of liquid in wells</td><td rowspan="2">Figure 1b and Additional file 6: Figure S5</td></tr><tr><td>b. Washing</td></tr><tr><td>3</td><td colspan="2">Square transfer (S-mode)</td><td>Fractional volume transfer</td><td>Additional file 2: Figure S1</td></tr><tr><td>4</td><td colspan="2">Z-direction transfer (Z-mode)</td><td>Normal transfer of liquid into wells</td><td>Figure 1b and Additional file 5: Figure S4</td></tr><tr><td>5</td><td colspan="2">X-direction transfer (X-mode)</td><td>Division of liquid in all wells</td><td>Additional file 7: Figure S6</td></tr><tr><td rowspan="2">6</td><td rowspan="2">Magnetic beads transfer (M-mode)</td><td>a. Beads recovery</td><td>Beads recovery</td><td>Additional file 8: Figure S7</td></tr><tr><td>b. Division of liquid</td><td>Division of liquid in all wells</td><td>Additional file 9: Figure S8</td></tr><tr><td>7</td><td colspan="2">Filtering (F-mode)</td><td>Filter-selective transfer</td><td>Figure 2a</td></tr><tr><td rowspan="2">PD</td><td rowspan="2">8</td><td rowspan="2">Pipette-dependent transfer (P-mode)</td><td>a. Manual</td><td>Manual transfer of liquid or beads</td><td>Additional file 10: Figure S9</td></tr><tr><td>b. Robotic</td><td>Robotic transfer of liquid or beads</td><td>Additional file 3: Figure S2</td></tr></table> |
d9a5e0918cbf7ff712a32358fea707e0b238b2558a9e35e158036d2411c375dd.png | complex | <table><tr><td>Gene</td><td>Sequence (5′-3′)</td><td>Product size (bp)</td></tr><tr><td rowspan="2">IL-6</td><td>For: CCTGACCCAACCACAAATGC</td><td rowspan="2">646</td></tr><tr><td>Rev: CCTTAAAGCTGCGCAGAATGA</td></tr><tr><td rowspan="2">IL-8</td><td>For: CTTTCCACCCCAAATTTATCAAAG</td><td rowspan="2">264</td></tr><tr><td>Rev: AGAGCTCTCTTCCATCAGAAAGCT</td></tr><tr><td rowspan="2">GAPDH</td><td>For: ACACCCACTCCTCCACCTTT</td><td rowspan="2">199</td></tr><tr><td>Rev: TAGCCAAATTCGTTGTCATACC</td></tr></table> |
17e11fed2b13ed3288c35e659a7583d6fcd4d4ccd6ec1929b4c254d7f1d4deb7.png | complex | <table><tr><td></td><td colspan="2">Before SS exposure on PND59</td><td colspan="2">After SS exposure on PND59</td></tr><tr><td>Group</td><td>R<sub>L</sub></td><td>C<sub>dyn</sub></td><td>R<sub>L</sub></td><td>C<sub>dyn</sub></td></tr><tr><td>GD7 SS</td><td>1.12 ± 0.11</td><td>0.053 ± 0.014</td><td>1.18 ± 0.19</td><td>0.046 ± 0.016</td></tr><tr><td>GD7 FA</td><td>1.04 ± 0.13</td><td>0.058 ± 0.016</td><td>1.11 ± 0.11</td><td>0.054 ± 0.017</td></tr><tr><td>PND2 SS</td><td>1.01 ± 0.09</td><td>0.065 ± 0.011</td><td>1.09 ± 0.13</td><td>0.053 ± 0.012</td></tr><tr><td>PND2 FA</td><td>0.94 ± 0.12</td><td>0.069 ± 0.016</td><td>1.03 ± 0.15</td><td>0.059 ± 0.007</td></tr><tr><td>PND21 SS</td><td>1.08 ± 0.05</td><td>0.062 ± 0.008</td><td>1.02 ± 0.10</td><td>0.069 ± 0.011</td></tr><tr><td>PND21 FA</td><td>1.01 ± 0.08</td><td>0.067 ± 0.007</td><td>0.96 ± 0.12</td><td>0.072 ± 0.014</td></tr></table> |
01e42bd2b7f572b8c71342529844a1ffed76cca443130bf44304d53caa99445b.png | complex | <table><tr><td></td><td colspan="2">EAPs for sensing</td></tr><tr><td></td><td>pros</td><td>cons</td></tr><tr><td colspan="3">ionic EAPs</td></tr><tr><td> conducting polymers</td><td>chemical stability, miniaturization, facile fabrication process, low-cost, low-weight, biocompatibility, soft, multiformable (sheet, film, tubular, trilayer), response to mechanical, electrical, chemical and thermal stimulation</td><td>insufficient adhesion onto substrate, fragile upon mechanical and thermal loading</td></tr><tr><td> ionic polymer–metal composites</td><td>low-weight, biocompatibility, miniaturization, soft, large produced voltage signal, sensitive to large bending deformation, ability to work in wet environments</td><td>hysteresis, sensitive to moisture and temperature during operation, operation limited to low temperature due to liquid electrolyte, slow response</td></tr><tr><td> carbon nanotubes</td><td>high surface area to volume, high sensitivity, miniaturization, directional mechanical and electrical properties</td><td>expensive, slow response, difficult to control intrinsic properties during fabrication</td></tr><tr><td colspan="3">electronic EAPs</td></tr><tr><td> dielectric elastomers</td><td>large sensing range, low-cost, light-weight, stability in many working cycles, and capability as self-sensing actuators</td><td>defect-sensitive, rare for stress measurement, not sensitive to compression in normal direction, may be affected by temperature</td></tr><tr><td> liquid-crystal elastomers</td><td>potential for high strain changes, potential high sensitivity to strain</td><td>complex and expensive synthesis and processing of the materials</td></tr><tr><td> piezoelectric polymers</td><td>wide bandwidth, fast electromechanical response, relatively low-power requirements, high generative forces</td><td>relatively low output performance originating from charge dissipation. Some materials need to be stretched and poled to gain higher output</td></tr></table> |
17ee5e64ae19261937a50d51eb28461e52cb12cea97790cd67571e6e87e21394.png | simple | <table><tr><td>Model</td><td>Regression coefficient</td><td>[95% CI]</td><td>p</td></tr><tr><td>Intercept</td><td>-17.15</td><td>[-18.94;-14.86]</td><td>-</td></tr><tr><td>Distance</td><td>-3.21</td><td>[-6.17;-1.74]</td><td>0.021</td></tr><tr><td>Biotope</td><td></td><td></td><td></td></tr><tr><td> Clear water</td><td>0</td><td>-</td><td>-</td></tr><tr><td> Rush wetland</td><td>0.92</td><td>[-0.64;3.03]</td><td>0.25</td></tr><tr><td> Rice field</td><td>17.67</td><td>[15.38;19.45]</td><td>0.005</td></tr><tr><td> Reeds</td><td>14.48</td><td>[-0.12;16.59]</td><td>0.084</td></tr><tr><td> Marshes with <i>Scirpus</i></td><td>17.50</td><td>[14.99;19.24]</td><td>0.009</td></tr></table> |
583e4dc493b8cad30bb2e19fe01c8ab94ef34b927c0067fcb8249435477d9cf6.png | simple | <table><tr><td>Drug resistant plasmid Name</td><td>Antimicrobial drug</td><td>Drug resistance plasmid MIC (ug/ml)</td><td>Empty vector MIC (ug/ml)</td><td>Fold increase</td></tr><tr><td>pAMP</td><td>ampicillin</td><td>16</td><td>4</td><td>4</td></tr><tr><td>pAMP</td><td>piperacillin</td><td>3</td><td>2</td><td>1.5</td></tr><tr><td>pAMP</td><td>cefotaxime</td><td><.25</td><td><.25</td><td>0</td></tr><tr><td>pAMP</td><td>ceftazidime</td><td><.5</td><td><.5</td><td>0</td></tr><tr><td>pAMP</td><td>cefepime</td><td>0.064</td><td>0.094</td><td>0.68</td></tr><tr><td>pAMP</td><td>Aztreonam</td><td>0.19</td><td>0.125</td><td>1.5</td></tr><tr><td>pAMP</td><td>Imipenem</td><td>0.25</td><td>0.25</td><td>0</td></tr><tr><td>pCIP</td><td>ciprofloxacin</td><td>0.125</td><td><0.002</td><td>>62.5</td></tr><tr><td>pCIP</td><td>levofloxacin</td><td>0.38</td><td>0.012</td><td>31.7</td></tr><tr><td>pCIP</td><td>Ampicillin</td><td>6</td><td>4</td><td>1.5</td></tr><tr><td>pCIP</td><td>piperacillin</td><td>3</td><td>2</td><td>1.5</td></tr><tr><td>pCIP</td><td>ceftazidime</td><td><.5</td><td><.5</td><td>0</td></tr><tr><td>pCIP</td><td>cefotaxime</td><td><.25</td><td><.25</td><td>0</td></tr><tr><td>pCIP</td><td>cefepime</td><td>0.125</td><td>0.094</td><td>1.3</td></tr><tr><td>pCIP</td><td>Imipenem</td><td>0.25</td><td>0.25</td><td>0</td></tr><tr><td>pTMP</td><td>trimethoprim</td><td>>32</td><td>0.124</td><td>>258</td></tr><tr><td>pTMP</td><td>trimethoprim- sulfamethoxazole</td><td>0.5</td><td>0.064</td><td>7.8</td></tr><tr><td>pAZT</td><td>Aztreonam</td><td>12</td><td>0.125</td><td>96</td></tr><tr><td>pAZT</td><td>cefepime</td><td>1</td><td>0.094</td><td>10.6</td></tr><tr><td>pAZT</td><td>ceftazidime</td><td>16</td><td>0.5</td><td>32</td></tr><tr><td>pAZT</td><td>piperacillin</td><td>12</td><td>2</td><td>6</td></tr><tr><td>pSXT</td><td>trimethoprim-sulfamethoxazole</td><td>1</td><td>0.064</td><td>15.6</td></tr><tr><td>pSXT</td><td>trimethoprim</td><td>>32</td><td>0.125</td><td>>256</td></tr><tr><td>pPRP:1B</td><td>ciprofloxacin</td><td>0.125</td><td>0.016</td><td>7.8</td></tr><tr><td>pPRP:1B</td><td>levofloxacin</td><td>0.25</td><td>0.047</td><td>5.3</td></tr></table> |
0af6ac92797bf484b2eeb99dcb76ff8c208d1f13662116302e8c979d65f9ce8b.png | simple | <table><tr><td>Primers</td><td>Sequences</td><td>Denaturation</td><td>annealing</td><td>Cycles</td><td>PCR products</td></tr><tr><td>HGF: ForwardReverse</td><td>5'-CAGAGGGACAAAGGAAAAGAA-3'5'-GCAAGTGAATGGAAGTCCTTTA-3'</td><td>94°C, 15s</td><td>58°C, 60s</td><td>40</td><td>167 bp</td></tr><tr><td>KGF: ForwardReverse</td><td>5'-GAACAAGGAAGGAAAACTCTATGCAA-3'5'-AAGTGGGCTGTTTTTTGTTCTTTCT-3'</td><td>94°C, 15s</td><td>60°C, 60s</td><td>40</td><td>201 bp</td></tr><tr><td>HGF-R: ForwardReverse</td><td>5'-GTTTACTTGTTGCAAGGGAGAAGACT-3'5'-TAGGGTGCCAGCATTTTAGCA-3'</td><td>94°C, 15s</td><td>58°C, 60s</td><td>40</td><td>88 bp</td></tr><tr><td>KGF-R: ForwardReverse</td><td>5'-TTAAGCAGGAGCATCGCATTG-3'5'-AACATCCAGGTGGTACGTGTGAT-3'</td><td>94°C, 15s</td><td>60°C, 60s</td><td>40</td><td>151 bp</td></tr><tr><td>Ubiquitin-c: ForwardReverse</td><td>5'-CACTTGGTCCTGCGCTTGA-3'5'-TTTTTTGGGAATGCAACAACTTT-3'</td><td>94°C, 15s</td><td>60°C, 60s</td><td>40</td><td>105 bp</td></tr></table> |
916c4afe7cc2fe866bdeab009fc832d9ebe97987e8b072063b6f9ba766f4a6e6.png | simple | <table><tr><td>Base value</td><td>Esmolol group (<i>n</i> = 75)</td><td>Control group (<i>n</i> = 76)</td><td><i>t</i>/<i>χ</i><sup>2</sup></td><td><i>P</i></td></tr><tr><td>Male, <i>n</i> (%)</td><td>54 (72.0)</td><td>53 (69.7)</td><td>0.094</td><td>0.760</td></tr><tr><td>APACHE-II score, mean ± standard deviation</td><td>24.20 ± 7.66</td><td>25.46 ± 7.83</td><td>−0.999</td><td>0.319</td></tr><tr><td>HR, mean ± standard deviation</td><td>125.04 ± 13.28</td><td>127.21 ± 13.88</td><td>−0.982</td><td>0.328</td></tr><tr><td>MAP, mean ± standard deviation</td><td>74.71 ± 7.28</td><td>75.89 ± 6.61</td><td>−1.051</td><td>0.295</td></tr><tr><td>CVP, mean ± standard deviation</td><td>12.45 ± 3.16</td><td>11.99 ± 3.35</td><td>0.881</td><td>0.380</td></tr><tr><td>IS, mean ± standard deviation</td><td>10.99 ± 2.08</td><td>11.11 ± 1.81</td><td>−0.374</td><td>0.709</td></tr><tr><td>Lac, mean ± standard deviation</td><td>8.98 ± 3.09</td><td>9.74 ± 4.05</td><td>−1.301</td><td>0.195</td></tr><tr><td>P(va)CO<sub>2</sub>, mean ± standard deviation</td><td>9.54 ± 3.89</td><td>10.12 ± 3.52</td><td>−0.947</td><td>0.345</td></tr><tr><td>ScvO<sub>2</sub>, mean ± standard deviation</td><td>0.77 ± 0.06</td><td>0.78 ± 0.06</td><td>−0.537</td><td>0.592</td></tr></table> |
96066addda506f321b3cce3a8d1f24f25a0c9a5bddc4af3e43aba42e481b57dd.png | complex | <table><tr><td rowspan="2" colspan="2"></td><td colspan="2">Inter-rater</td><td colspan="2">Intra-rater</td></tr><tr><td>FT</td><td>ROl</td><td>FT</td><td>ROl</td></tr><tr><td>L4 (N=103)</td><td>FA R/L</td><td>0.89/0.89</td><td>0.68/0.54</td><td>0.79/0.83</td><td>0.78/0.78</td></tr><tr><td></td><td>ADC R/L</td><td>0.96/0.93</td><td>0.85/0.85</td><td>0.87/0.93</td><td>0.96/0.86</td></tr><tr><td>L5 (N=127)</td><td>FA R/L</td><td>0.96/0.95</td><td>0.65/0.77</td><td>0.93/0.93</td><td>0.69/0.79</td></tr><tr><td></td><td>ADC R/L</td><td>0.96/0.96</td><td>0.82/0.93</td><td>0.96/0.95</td><td>0.88/0.90</td></tr><tr><td>S1 (N=135)</td><td>FA R/L</td><td>0.96/0.98</td><td>0.85/0.90</td><td>0.96/0.95</td><td>0.77/0.87</td></tr><tr><td></td><td>ADC R/L</td><td>0.96/0.93</td><td>0.92/0.95</td><td>0.98/0.98</td><td>0.97/0.96</td></tr></table> |
ba440d9d0cc415c4101267033e91fa9f641207821f8d479e03dc1291468a54b9.png | complex | <table><tr><td>Virus</td><td>Dilution</td><td>Virus isolation</td><td>Real time RT-PCR</td><td>CT</td></tr><tr><td>WEEV</td><td>10<sup>-1</sup></td><td>4/4</td><td>+</td><td>15.25</td></tr><tr><td></td><td>10<sup>-2</sup></td><td>4/4</td><td>+</td><td>18.29</td></tr><tr><td></td><td>10<sup>-3</sup></td><td>4/4</td><td>+</td><td>22.02</td></tr><tr><td></td><td>10<sup>-4</sup></td><td>4/4</td><td>+</td><td>25.49</td></tr><tr><td></td><td>10<sup>-5</sup></td><td>4/4</td><td>+</td><td>29.28</td></tr><tr><td></td><td>10<sup>-6</sup></td><td>2/4</td><td>+</td><td>32.79</td></tr><tr><td></td><td>10<sup>-7</sup></td><td>0/4</td><td>+</td><td>36.03</td></tr><tr><td></td><td>10<sup>-8</sup></td><td>0/4</td><td>-</td><td></td></tr><tr><td colspan="5">TCID<sub>50</sub>: 10<sup>6</sup>/0.1 ml</td></tr><tr><td>EEEV</td><td>10<sup>-1</sup></td><td>4/4</td><td>+</td><td>11.37</td></tr><tr><td></td><td>10<sup>-2</sup></td><td>4/4</td><td>+</td><td>16.25</td></tr><tr><td></td><td>10<sup>-3</sup></td><td>4/4</td><td>+</td><td>18.54</td></tr><tr><td></td><td>10<sup>-4</sup></td><td>4/4</td><td>+</td><td>22.03</td></tr><tr><td></td><td>10<sup>-5</sup></td><td>4/4</td><td>+</td><td>27.35</td></tr><tr><td></td><td>10<sup>-6</sup></td><td>2/4</td><td>+</td><td>30.18</td></tr><tr><td></td><td>10<sup>-7</sup></td><td>1/4</td><td>+</td><td>34.79</td></tr><tr><td></td><td>10<sup>-8</sup></td><td>0/4</td><td>+</td><td>37.59</td></tr><tr><td colspan="5">TCID<sub>50</sub>: 10<sup>6.25</sup>/0.1 ml</td></tr></table> |
a499781545d1e08bff4367e036f9f19f8a913b7eae6829ca739bd0cf484aaca6.png | simple | <table><tr><td><i>True/False item</i></td><td>Correct answer</td><td>% correct*</td><td><i>True/False item</i></td><td>Correct answer</td><td>% correct*</td></tr><tr><td>HIV/AIDS KNOWLEDGE</td><td> </td><td> </td><td>OVERDOSE KNOWLEDGE</td><td> </td><td> </td></tr><tr><td>When a couple decides that they are ONLY going to have sex with each other, they no longer need to use condoms to prevent HIV.</td><td>F</td><td>66.9 (62.1, 71.8)</td><td>Causing physical pain will help keep someone who is overdosing conscious or alive.</td><td>F</td><td>36.9 (31.9, 41.9)</td></tr><tr><td>The fewer sex partners you have in your life, the less likely you are to get HIV.</td><td>T</td><td>66.0 (61.2, 70.9)</td><td>Fatal ODs are more likely to happen when people use alone.</td><td>T</td><td>89.5 (86.4, 92.6)</td></tr><tr><td>People can still transmit the HIV/AIDS virus even if they test negative for the virus.</td><td>T</td><td>45.2 (40.1, 50.3)</td><td>People are more likely to have an OD if they use soon after getting out of a government center, prison, or detoxification program.</td><td>T</td><td>84.8 (81.1, 88.5)</td></tr><tr><td>Most people who have HIV know they have it.</td><td>F</td><td>52.1 (46.9, 57.2)</td><td>Most heroin OD deaths happen very quickly, in less than 15 minutes after taking the drugs.</td><td>F</td><td>9.8 (6.7, 12.8)</td></tr><tr><td>HEPATITIS KNOWLEDGE</td><td> </td><td> </td><td>It is easy to tell the difference between a “heavy nod” and a heroin overdose.</td><td>F</td><td>10.1 (7.0, 13.2)</td></tr><tr><td>Hepatitis can cause liver cancer.</td><td>T</td><td>72.1 (67.5, 76.7)</td><td>Sweating and anxiety are signs of a heroin OD.</td><td>F</td><td>58.0 (52.9, 63.1)</td></tr><tr><td>HIV is easier to transmit than hepatitis.</td><td>F</td><td>46.4 (41.3,51.6)</td><td>Injecting water can slow or reverse the effects of an opioid overdose</td><td>F</td><td>30.5 (25.7, 35.2)</td></tr><tr><td>You will be able to recognize if any individual is infected with hepatitis.</td><td>F</td><td>40.9 (35.8, 46.0)</td><td>Someone who is overdosing should be immediately placed on their back.</td><td>F</td><td>18.3 (14.3, 22.3)</td></tr><tr><td>Most people infected with hepatitis know that they have the disease.</td><td>F</td><td>46.4 (41.2, 51.6)</td><td>Naloxone is a medication for reversing the effects of a heroin OD.</td><td>T</td><td>47.7 (42.4, 53.0)</td></tr><tr><td>Drinking alcohol worsens the course of hepatitis C.</td><td>T</td><td>84.2 (80.4, 87.9)</td><td>Naloxone must be injected into a vein.</td><td>F</td><td>26.9 (22.2, 31.7)</td></tr><tr><td>You are more likely to get hepatitis B than hepatitis C by having unprotected sex.</td><td>T</td><td>54.3 (49.1, 49.4)</td><td>Naloxone will reverse a stimulant overdose.</td><td>F</td><td>24.8 (20.3, 29.4)</td></tr></table> |
996ad56d35aed35bda33b893ec65fd18a510690a4a7621355d17429df7ddeba7.png | simple | <table><tr><td>Productivity software</td><td>Microsoft Office</td></tr><tr><td></td><td>Endnote</td></tr><tr><td></td><td>Toolbook Runtime (with modules)</td></tr><tr><td>Medical Software (Anatomy)</td><td>A.D.A.M</td></tr><tr><td></td><td>Anatomy TV</td></tr><tr><td></td><td>Grant's Atlas of Dynamic Human Anatomy</td></tr><tr><td></td><td>Netter</td></tr><tr><td></td><td>Imaging Modalities</td></tr><tr><td></td><td>D.A.R.T.O.S.</td></tr><tr><td>Medical Software (Biochemistry)</td><td>Buffers</td></tr><tr><td></td><td>Clustal X</td></tr><tr><td></td><td>Cn3D</td></tr><tr><td></td><td>Genedoc</td></tr><tr><td></td><td>Graphpad Prism</td></tr><tr><td></td><td>Growcyt</td></tr><tr><td></td><td>Hypercell 98</td></tr><tr><td></td><td>Image J</td></tr><tr><td></td><td>Interactive biochemistry</td></tr><tr><td></td><td>NjPlot</td></tr><tr><td></td><td>Protein explorer</td></tr><tr><td></td><td>Protein purification lab</td></tr><tr><td></td><td>RasMol 2.6</td></tr><tr><td></td><td>Spectrophotmetry</td></tr><tr><td></td><td>Swiss PDB Viewer</td></tr><tr><td></td><td>Trace</td></tr><tr><td>Medical Software (Nutrition and Dietetics)</td><td>FoodWorks</td></tr><tr><td></td><td>SERV v5.5e</td></tr><tr><td>Medical Software (Pharmacology)</td><td>Pharma-Cal-Ogy</td></tr><tr><td>Medical Software (Physiology)</td><td>Acid Base</td></tr><tr><td></td><td>Exercise Physiology</td></tr></table> |
a314401b28b8ce768194f9f9c96c217f5451a17fdb4bb73f5c3662df58c60b65.png | simple | <table><tr><td>Number</td><td>Scenario</td></tr><tr><td>1</td><td>Human papilloma virus positive state</td></tr><tr><td>2</td><td>Cervical intraepithelial neoplasia grade I</td></tr><tr><td>3</td><td>Cervical intraepithelial neoplasia grade II/III</td></tr><tr><td>4</td><td>Cervical cancer requiring simple or radical hysterectomy</td></tr><tr><td>5</td><td>Cervical cancer requiring radical hysterectomy and subsequent radiotherapy (and chemotherapy)</td></tr><tr><td>6</td><td>Cervical cancer requiring chemoradiation therapy</td></tr><tr><td>7</td><td>Cervical cancer requiring chemotherapy without surgery</td></tr><tr><td>8</td><td>Condyloma (genital warts [condyloma acuminatum])</td></tr></table> |
3d10f0c41b2a452e881f2860f12bf80a5640c8d66c02e7f38eb72006e26a2159.png | complex | <table><tr><td><i>District</i></td><td><i>Locality (n)</i></td><td><i>Seroprevalence % (proportion)</i></td><td><i>95% C.I.</i></td><td><i>P-value</i></td></tr><tr><td rowspan="5">Charsadda</td><td>Ataki (38)</td><td>36.8 (14/38)</td><td>21.8–54.0</td><td>Χ<sup>2</sup> = 7.63</td></tr><tr><td>Batagram (29)</td><td>55.2 (16/29)</td><td>35.7–73.6</td><td><i>P</i> = 0.106</td></tr><tr><td>Penda Khel (63)</td><td>50.8 (32/63)</td><td>37.9–63.6</td><td></td></tr><tr><td>Sarderi (31)</td><td>38.7 (12/31)</td><td>21.8–57.8</td><td></td></tr><tr><td>Torenzai (32)</td><td>65.6 (21/32)</td><td>46.8–81.4</td><td></td></tr><tr><td rowspan="4">Peshawar</td><td>Ganjkohati (56)</td><td>32.1 (18/56)</td><td>20.3–46.0</td><td>χ<sup>2</sup> = 9.39</td></tr><tr><td>Badabir (40)</td><td>22.5 (9/40)</td><td>10.8–38.5</td><td><i>P</i> = 0.024</td></tr><tr><td>Pandu (50)</td><td>40.0 (20/50)</td><td>26.4–54.8</td><td></td></tr><tr><td>Ring Road (54)</td><td>14.8 (8/54)</td><td>6.6–27.1</td><td></td></tr><tr><td>Total</td><td></td><td>38.2 (150/393)</td><td>33.3–43.2</td><td></td></tr></table> |
eaf67a2fc851b5f596eb04d94dee3bd02e943e0004be7245213b5fae5c5deebf.png | complex | <table><tr><td>Parameter</td><td>HMA All Lines (<i>n</i> = 88)</td><td>First-Line HMA (<i>n</i> = 41)</td><td>First-Line ICT (<i>n</i> = 122)</td><td><i>p</i>-Value First-Line HMA vs. ICT</td></tr><tr><td>Median age at diagnosis, years</td><td>69</td><td>73</td><td>60</td><td>0.1698</td></tr><tr><td> (min–max)</td><td>(28–88)</td><td>(44–88)</td><td>(20–86)</td><td></td></tr><tr><td>Male gender, <i>n</i> (%)</td><td>54 (61)</td><td>26 (63)</td><td>88 (72)</td><td>0.3919</td></tr><tr><td>BM blasts at start of treatment</td><td></td><td></td><td></td><td></td></tr><tr><td> Median</td><td>22</td><td>22</td><td>24</td><td>0.8576</td></tr><tr><td> Mean (Standard Deviation)</td><td>25.8 (17.2)</td><td>25.8 (15.9)</td><td>27.1 (15.8)</td><td></td></tr><tr><td> Unknown, <i>n</i> (%)</td><td>12 (14)</td><td>2 (5)</td><td>6 (5)</td><td></td></tr><tr><td>Hemoglobin at start of treatment, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> ≤10 g/dL</td><td>55 (63)</td><td>32 (78)</td><td>32/64 (50)</td><td>1.00</td></tr><tr><td> Pts. with unknown hemoglobin</td><td>3 (3)</td><td>0 (0)</td><td>71 (58)</td><td></td></tr><tr><td rowspan="2">Median WBC count at start of treatment, ×10<sup>9</sup>/L (min–max)</td><td>2.35</td><td>2.42</td><td>1.81</td><td>0.7294</td></tr><tr><td>(0.1–32.3)</td><td>(0.6–24.0)</td><td>(0.2–23.9)</td><td></td></tr><tr><td>Neutrophil count at start of treatment, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> ≤ 0.5 × 10<sup>9</sup>/L</td><td>34 (39)</td><td>18 (44)</td><td>18/57 (31)</td><td>0.7326</td></tr><tr><td> Pts. with unknown neutrophil count</td><td>5 (6)</td><td>1 (2)</td><td>79 (65)</td><td></td></tr><tr><td>Platelet count at start of treatment, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> ≤50 × 10<sup>9</sup>/L</td><td>54 (61)</td><td>24 (69)</td><td>62 (51)</td><td>0.8673</td></tr><tr><td> Unknown</td><td>3 (3)</td><td>0 (0)</td><td>10 (8)</td><td></td></tr><tr><td>AML subtype, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> Primary</td><td>66 (75)</td><td>35 (85)</td><td>81 (66)</td><td>0.4373</td></tr><tr><td> Secondary</td><td>11 (13)</td><td>4 (10)</td><td>17 (14)</td><td></td></tr><tr><td> Unknown</td><td>11 (13)</td><td>2 (5)</td><td>24 (20)</td><td></td></tr><tr><td>MRC cytogenetic risk group, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> Good risk</td><td>1 (1)</td><td>0 (0)</td><td>0 (0)</td><td>0.6943</td></tr><tr><td> Intermediate risk</td><td>39 (44)</td><td>17 (42)</td><td>51 (42)</td><td></td></tr><tr><td> Poor risk</td><td>45 (51)</td><td>22 (54)</td><td>53 (43)</td><td></td></tr><tr><td> Unknown</td><td>3 (3)</td><td>2 (5)</td><td>18 (15)</td><td></td></tr></table> |
407a1fce2a86dcb140851f5bb8e67804dc21f8b1573b3f580f5ec708229d93cd.png | simple | <table><tr><td>Molecular Category</td><td>TGFβ Sub-Family Pathway <sup>1</sup></td><td>BMP Sub-Family Pathway</td></tr><tr><td>Ligands</td><td>TGFβs, ActivinsGDF8/9/10/11, BMP3, Nodal</td><td>BMP2/4/5/6/7/8/9/10, GDF1/3/5/6/7, MIS</td></tr><tr><td>Type II receptors</td><td>TβRII, ActRIIA, ActRIIB</td><td>BMPRII, ActRIIA, ActRIIB</td></tr><tr><td>Type I receptors</td><td>ALK4, TβRI (ALK5), ALK7</td><td>ALK1/2, BMPR1A (ALK3), BMPR1B (ALK6)</td></tr><tr><td>R-Smad</td><td>Smad2/3</td><td>Smad1/5/8</td></tr><tr><td>Co-Smad</td><td>Smad4</td><td>Smad4</td></tr><tr><td>I-Smad</td><td>Smad7</td><td>Smad6/7</td></tr></table> |
79c450f12d952e2df231274683ff81dd4fde3063b8609099e96092e76bd1f4e6.png | simple | <table><tr><td>Comparison</td><td>p value</td><td>r value</td></tr><tr><td>Quads Strength and TWT</td><td></td><td></td></tr><tr><td>Baseline</td><td>0.003</td><td>-0.688</td></tr><tr><td>Week 6</td><td>0.003</td><td>-0.697</td></tr><tr><td>Week 12</td><td>0.005</td><td>-0.662</td></tr><tr><td>Quads Strength and TST</td><td></td><td></td></tr><tr><td>Baseline</td><td>0.008</td><td>-0.626</td></tr><tr><td>Preoperative</td><td>0.020</td><td>-0.552</td></tr><tr><td>Week 6</td><td>0.009</td><td>-0.618</td></tr><tr><td>Week 12</td><td>0.001</td><td>-0.776</td></tr><tr><td>Quads Strength and TCT</td><td></td><td></td></tr><tr><td>Preoperative</td><td>0.032</td><td>-0.508</td></tr><tr><td>WOMAC-Pain and TCT</td><td></td><td></td></tr><tr><td>Baseline</td><td>0.047</td><td>0.464</td></tr><tr><td>WOMAC-Function and TWT</td><td></td><td></td></tr><tr><td>Baseline</td><td>0.034</td><td>0.252</td></tr><tr><td>SF36-Physical Health and TWT</td><td></td><td></td></tr><tr><td>Baseline</td><td>0.009</td><td>-0.623</td></tr><tr><td>Week 12</td><td>0.041</td><td>-0.481</td></tr><tr><td>SF36-Physical Health and TST</td><td></td><td></td></tr><tr><td>Preoperative</td><td>0.039</td><td>-0.487</td></tr><tr><td>SF36-Mental Health and TCT</td><td></td><td></td></tr><tr><td>Week 12</td><td>0.026</td><td>-0.528</td></tr></table> |
6a87d352059f4e7569e8b77f376ad59b2ff6fa097a9eecf6122149e645d4ad7b.png | complex | <table><tr><td></td><td colspan="2">FMF</td><td></td></tr><tr><td></td><td>Rheumatic diseases (+)</td><td>Rheumatic diseases (–)</td><td></td></tr><tr><td></td><td><i>n</i> = 26</td><td><i>n</i> = 166</td><td><i>p</i></td></tr><tr><td>Male/female</td><td>4/22</td><td>79/87</td><td>0.002</td></tr><tr><td>Age at onset (years), mean ± SD</td><td>39.3 ± 15.8</td><td>29.0 ± 16.8</td><td>0.006</td></tr><tr><td>Fever</td><td>24 (92.3 %)</td><td>160 (96.4 %)</td><td>0.296</td></tr><tr><td>Frequencies of febrile attack (per month), mean ± SD</td><td>1.01 ± 0.59</td><td>1.06 ± 0.96</td><td>0.523</td></tr><tr><td>Duration of fever attack (days), mean ± SD</td><td>3.0 ± 2.2</td><td>3.8 ± 4.1</td><td>0.359</td></tr><tr><td>Abdominal pain</td><td>3 (11.5 %)</td><td>74 (44.6 %)</td><td>0.001</td></tr><tr><td>Thoracic pain</td><td>4 (15.4 %)</td><td>47 (28.3 %)</td><td>0.165</td></tr><tr><td>Arthritis</td><td>21 (80.8 %)</td><td>87 (52.4 %)</td><td>0.007</td></tr><tr><td>Erysipelas-like erythema</td><td>3 (11.5 %)</td><td>31 (18.7 %)</td><td>0.281</td></tr><tr><td>AA amyloidosis</td><td>0</td><td>7 (4.2 %)</td><td>0.355</td></tr><tr><td>Family history of periodic fever</td><td>1 (3.8 %)</td><td>38 (22.9 %)</td><td>0.025</td></tr></table> |
61850dd9c42f586607c810f443ff7ca086c53e94cd36a6f9e546936de94b7340.png | simple | <table><tr><td>MicroRNA</td><td>Location</td><td>Model</td><td>Response</td><td>References</td></tr><tr><td>miR-200c</td><td>Upstream</td><td><i>db</i>/<i>db</i> T2DM</td><td>Increase aorta endothelial dysfunction</td><td>[101]</td></tr><tr><td>miR-320</td><td>Upstream</td><td>High glucose treated HUVECs</td><td>Reduced expression of ET-1, VEGF, and FN</td><td>[102]</td></tr><tr><td>miR-133a</td><td>Upstream</td><td>STZ-induced diabetes</td><td>Prevent cardiac fibrosis</td><td>[103]</td></tr><tr><td>miR-1 and 6</td><td>Up stream</td><td>STZ-induced diabetes and high glucose treated NRVCs</td><td>Increase cardiomyocyte apoptosis</td><td>[104]</td></tr></table> |
00a8c9cba53e2b1eed21f546c8e9ba19a6213b782b86b3aaff31614d58038a6b.png | complex | <table><tr><td></td><td></td><td>Uncorrected T<sub>2</sub>Prep‐IR BOOST</td><td>Motion Corrected T<sub>2</sub>Prep‐IR BOOST</td><td></td></tr><tr><td rowspan="3">RCA</td><td>Length (cm)</td><td>7.03 ± 1.50</td><td>8.58 ± 2.27</td><td><i>P</i> < 0.02</td></tr><tr><td>%VS (4 cm)</td><td>36.54 ± 8.63</td><td>48.31 ± 6.71</td><td><i>P</i> < 0.001</td></tr><tr><td>%VS (tot)</td><td>37.96 ± 8.63</td><td>48.82 ± 4.63</td><td><i>P</i> < 0.001</td></tr><tr><td rowspan="3">LAD</td><td>Length (cm)</td><td>4.82 ± 3.78</td><td>7.92 ± 4.16</td><td><i>P</i> < 0.02</td></tr><tr><td>%VS (4 cm)</td><td>32.92 ± 16.08</td><td>48.82 ± 6.51</td><td><i>P</i> < 0.005</td></tr><tr><td>%VS (tot)</td><td>32.42 ± 15.15</td><td>48.12 ± 6.63</td><td><i>P</i> < 0.005</td></tr></table> |
07340370d126b78e2563e72ff0941560d3ded39cdafaf90cd73774d677828fef.png | simple | <table><tr><td>Site/size</td><td>Mean</td><td>StDev</td><td>Min</td><td>Med</td><td>Max</td></tr><tr><td>EF >100</td><td>0.02615</td><td>0.02849</td><td>0</td><td>0.0159</td><td>0.10568</td></tr><tr><td>EF >50 < 100</td><td>1.02039</td><td>0.02286</td><td>0</td><td>0.01761</td><td>0.07789</td></tr><tr><td>EF <50</td><td>0.04478</td><td>0.03933</td><td>0</td><td>0.04559</td><td>0.124</td></tr><tr><td>SE >100</td><td>*0.1589</td><td>0.03933</td><td>0.00677</td><td>0.131</td><td>0.4524</td></tr><tr><td>SE >50 < 100</td><td>*0.2121</td><td>0.167</td><td>0.0124</td><td>0.1976</td><td>0.6228</td></tr><tr><td>SE <50</td><td>*0.7170</td><td>0.477</td><td>0.0352</td><td>0.755</td><td>1.654</td></tr><tr><td>I >100</td><td>0.01564</td><td>0.02594</td><td>0</td><td>0.0124</td><td>0.11683</td></tr><tr><td>I >50 < 100</td><td>0.02883</td><td>0.03709</td><td>0</td><td>0.02067</td><td>0.15578</td></tr><tr><td>I <50</td><td>0.093</td><td>0.1135</td><td>0</td><td>0.0671</td><td>0.4284</td></tr></table> |
0a66f313c94e7f3a03368923c37332c871bdffc0f4135add86d2301ea0580a4b.png | complex | <table><tr><td> </td><td colspan="5"><i>Expression in A549</i></td></tr><tr><td> </td><td><i>Parental (fold)</i></td><td><i>Senescent RNA-seq (fold)</i></td><td><i>Senescent RT-PCR (fold)</i></td><td><i>Revertant RNA-seq (fold)</i></td><td><i>Revertant RT-PCR (fold)</i></td></tr><tr><td>NPTX1</td><td>1</td><td>23</td><td>40</td><td>4</td><td>6</td></tr><tr><td>IGF2</td><td>1</td><td>13</td><td>12</td><td>4.1</td><td>3.5</td></tr><tr><td>HAPLN3</td><td>1</td><td>10</td><td>38</td><td>2.8</td><td>7.4</td></tr><tr><td>CHAC1</td><td>1</td><td>25</td><td>22</td><td>4.2</td><td>2.7</td></tr><tr><td>BST2</td><td>1</td><td>207</td><td>62</td><td>10</td><td>1.5</td></tr><tr><td>C15orf48</td><td>1</td><td>207</td><td>9</td><td>10</td><td>2.5</td></tr><tr><td>NIPAL4</td><td>1</td><td>64</td><td>25</td><td>4.2</td><td>2.2</td></tr><tr><td>AGT</td><td>1</td><td>185</td><td>98</td><td>7.4</td><td>3</td></tr><tr><td>SPATA18</td><td>1</td><td>10</td><td>19</td><td>1.8</td><td>2</td></tr><tr><td>PIK3R2</td><td>1</td><td>6</td><td>9</td><td>1.9</td><td>3.6</td></tr><tr><td>MT1X</td><td>1</td><td>9</td><td>9</td><td>1.9</td><td>1.8</td></tr><tr><td>PAQR7</td><td>1</td><td>7</td><td>6</td><td>2.3</td><td>1.7</td></tr><tr><td>GJA1</td><td>1</td><td>5</td><td>10</td><td>2.4</td><td>3.2</td></tr><tr><td>LAPTM5</td><td>1</td><td>26</td><td>168</td><td>2.4</td><td>3.7</td></tr><tr><td>SP5</td><td>1</td><td>16</td><td>30</td><td>2.4</td><td>2.6</td></tr><tr><td>COL20A1</td><td>1</td><td>11</td><td>16</td><td>2.4</td><td>2.4</td></tr><tr><td>NAP1L3</td><td>1</td><td>43</td><td>48</td><td>2.5</td><td>2</td></tr><tr><td>FBXL21</td><td>1</td><td>28</td><td>14</td><td>2.5</td><td>3.5</td></tr><tr><td>Tmem26</td><td>1</td><td>88</td><td>28</td><td>2.5</td><td>3.3</td></tr><tr><td>CST1</td><td>1</td><td>7</td><td>11</td><td>2.8</td><td>4</td></tr><tr><td>SNAI2</td><td>1</td><td>25</td><td>74</td><td>2.8</td><td>5.3</td></tr><tr><td>TEN1</td><td>1</td><td>5</td><td>2</td><td>2.9</td><td>1.7</td></tr><tr><td>DYDC2</td><td>1</td><td>15</td><td>9</td><td>3</td><td>2</td></tr><tr><td>ZNF841</td><td>1</td><td>15</td><td>5</td><td>3</td><td>1.6</td></tr><tr><td>AMOT</td><td>1</td><td>7</td><td>28</td><td>3</td><td>6.2</td></tr><tr><td>BARX1</td><td>1</td><td>13</td><td>15</td><td>3</td><td>3.2</td></tr><tr><td>ABCA8</td><td>1</td><td>6</td><td>8</td><td>3</td><td>3.2</td></tr><tr><td>AIM1L</td><td>1</td><td>10</td><td>12</td><td>3.2</td><td>2.5</td></tr><tr><td>CDRT4</td><td>1</td><td>6</td><td>3</td><td>3.2</td><td>1.3</td></tr><tr><td>SLC2A3</td><td>1</td><td>18</td><td>14</td><td>3.3</td><td>2.5</td></tr><tr><td>CPE</td><td>1</td><td>5</td><td>7</td><td>3.6</td><td>4.4</td></tr><tr><td>TRO145</td><td>1</td><td>30</td><td>19</td><td>3.9</td><td>1.4</td></tr><tr><td>HOXD10</td><td>1</td><td>11</td><td>4</td><td>5</td><td>1.9</td></tr><tr><td>PIP</td><td>1</td><td>53</td><td>36</td><td>5.6</td><td>1.1</td></tr><tr><td>EMB</td><td>1</td><td>5</td><td>6</td><td>6.5</td><td>4.9</td></tr><tr><td>SERPINB4</td><td>1</td><td>26</td><td>2</td><td>7.9</td><td>1.6</td></tr><tr><td>QPRT3</td><td>1</td><td>119</td><td>24</td><td>20</td><td>2.7</td></tr><tr><td>SLC7A4</td><td>1</td><td>714</td><td>4</td><td>340</td><td>1</td></tr><tr><td>IFI44</td><td>1</td><td>395</td><td>4324</td><td>3</td><td>18</td></tr></table> |
0fbb76c05311a2649001250f59f9d69fb5c577d1d8176d0dafeb172d2dd0fe69.png | complex | <table><tr><td>Cheese sample</td><td>Area assessed</td><td><i>a</i> value at 144 days</td></tr><tr><td rowspan="4">Control</td><td>Top</td><td>−2.22</td></tr><tr><td>Side</td><td>−2.17</td></tr><tr><td>Base</td><td>−2.32</td></tr><tr><td>Center</td><td>−2.38</td></tr><tr><td rowspan="4">Exp1</td><td>Top</td><td>−2.21</td></tr><tr><td>Side</td><td>−2.28</td></tr><tr><td>Base</td><td>−2.21</td></tr><tr><td>Center</td><td>−1.95</td></tr><tr><td rowspan="4">Exp2</td><td>Top</td><td>−2.18</td></tr><tr><td>Side</td><td>−2.16</td></tr><tr><td>Base</td><td>−2.10</td></tr><tr><td>Center</td><td>−1.34<sup>b</sup></td></tr><tr><td rowspan="4">Exp3</td><td>Top</td><td>−2.14</td></tr><tr><td>Side</td><td>−2.35</td></tr><tr><td>Base</td><td>−2.13</td></tr><tr><td>Center</td><td>−1.82</td></tr></table> |
0906d2635be23c4a54c7dc593ba6e8244ca9d787d370f2c7f3800a2757cdcbe6.png | simple | <table><tr><td></td><td>Low Rate </td><td>Medium Rate </td><td>High Rate </td><td><i>p</i>-value </td></tr><tr><td>Countries with implemented screening programmes</td><td>22% (2/9)</td><td>67% (6/9)</td><td>89% (8/9)</td><td>0.014</td></tr><tr><td>Countries with guidelines for screening</td><td>11% (1/9)</td><td>78% (7/9)</td><td>78% (7/9)</td><td>0.005</td></tr></table> |
2a48d7da3e0bdf648a3d89310f3b4fa1a604001ca2c9c3e47fca6b7bcd891e36.png | complex | <table><tr><td></td><td colspan="4">Reported obstetric complications or near misses</td></tr><tr><td>Independent variables</td><td>Eclampsia</td><td>Hemorrhage</td><td>Sepsis</td><td>Obstructed labor</td></tr><tr><td></td><td>(n = 324)</td><td>(n = 4,945)</td><td>(n = 3,120)</td><td>(n = 2,847)</td></tr><tr><td></td><td>Odds ratio</td><td>Odds ratio</td><td>Odds ratio</td><td>Odds ratio</td></tr><tr><td>Biological factors</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Age 18–35 years (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Age <18 years</td><td>1.35***</td><td>1.20***</td><td>1.18***</td><td>1.27***</td></tr><tr><td>Age >35 years</td><td>1.34***</td><td>1.27***</td><td>1.19*</td><td>1.21***</td></tr><tr><td><i>Parity 1–2 (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Nulliparity</td><td>1.13**</td><td>1.10**</td><td>1.14**</td><td>1.30***</td></tr><tr><td>Parity >2</td><td>1.12</td><td>1.09</td><td>1.05</td><td>1.10</td></tr><tr><td><i>No previous stillbirth or miscarriage (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Adverse obstetric history</td><td>1.18***</td><td>1.06**</td><td>1.12**</td><td>1.14***</td></tr><tr><td><i>MUAC ≥ 21.5 cm (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>MUAC < 21.5 cm</td><td>1.04</td><td>1.12*</td><td>1.16*</td><td>1.05</td></tr><tr><td>Socioeconomic factors</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Wealth index – Lowest quartile (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Wealth index - 2<sup>nd</sup> quartile</td><td>1.00</td><td>1.01</td><td>1.02</td><td>1.00</td></tr><tr><td>Wealth index - 3<sup>rd</sup> quartile</td><td>1.01</td><td>1.02</td><td>1.00</td><td>1.00</td></tr><tr><td>Wealth index - Highest quartile</td><td>1.00</td><td>1.03</td><td>1.05</td><td>1.02</td></tr><tr><td><i>Maternal illiteracy (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Maternal literacy</td><td>1.01</td><td>1.01</td><td>1.04</td><td>1.03</td></tr><tr><td>Psychosocial factors</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Both partners wanted pregnancy (ref)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Only one partner wanted pregnancy</td><td>1.02</td><td>1.06</td><td>1.08</td><td>1.07</td></tr><tr><td>Neither partner wanted pregnancy</td><td>1.02</td><td>1.40***</td><td>1.37***</td><td>1.28***</td></tr></table> |
98db322d9ee49e419b1986da46dfde27a8e2a7c329a0bf9f9c8e6a5081d809bd.png | complex | <table><tr><td></td><td colspan="3">Swollen joints</td><td colspan="3">Tender joints</td></tr><tr><td></td><td>32JC<sup>- </sup>(<i>n </i>= 760)</td><td>28JC<sup>-</sup>/32JC<sup>+ </sup>(<i>n </i>= 38)</td><td><i>p</i></td><td>32JC<sup>- </sup>(<i>n </i>= 1,120)</td><td>28JC<sup>-</sup>/32JC<sup>+ </sup>(<i>n </i>= 102)</td><td><i>p</i></td></tr><tr><td>SDAI</td><td>6.45</td><td>8.93</td><td>0.03</td><td>7.95</td><td>10.91</td><td>0.00</td></tr><tr><td>DAS28</td><td>2.65</td><td>2.92</td><td>0.11</td><td>2.65</td><td>2.97</td><td>0.00</td></tr><tr><td>C-reactive protein (mg/dl)</td><td>1.25</td><td>1.43</td><td>0.56</td><td>1.38</td><td>1.52</td><td>0.42</td></tr><tr><td>Pain (mm VAS)</td><td>23</td><td>36</td><td>0.00</td><td>20</td><td>34</td><td>0.00</td></tr><tr><td>Patient global (mm VAS)</td><td>22</td><td>39</td><td>0.00</td><td>21</td><td>35</td><td>0.00</td></tr><tr><td>Physician global (mm VAS)</td><td>17</td><td>19</td><td>0.51</td><td>12</td><td>25</td><td>0.00</td></tr></table> |
37dd042ad11ecbeba4c91c206ebc5e7228e187ae5998c9e0e52ce989593357eb.png | simple | <table><tr><td>Outcome variable</td><td>ESeC 1</td><td>ESeC 2</td><td>ESeC 3</td><td><i>p</i></td></tr><tr><td><i>ESS score</i></td><td>9.24±5.27</td><td>9.41±4.9</td><td>8.92±5.2</td><td>0.645</td></tr><tr><td>Median (IQR)</td><td>8.5 (5-12)</td><td>9 (6-13)</td><td>8 (5-12)</td><td> </td></tr><tr><td>Missing data</td><td>1 (1)</td><td>2 (2.9)</td><td>4 (3.5)</td><td>0.485</td></tr><tr><td><i>AHI</i></td><td>39.81±27.01</td><td>50.51±30.43</td><td>41.94±24.26</td><td>0.059</td></tr><tr><td>Median (IQR)</td><td>31.7(16.7-63.5)</td><td>45 (24-78.6)</td><td>39.3 (22-64.4)</td><td> </td></tr><tr><td>AHI groups</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i><15</i></td><td>23 (23.2)</td><td>6 (8.6)</td><td>18 (15.9)</td><td>0.133</td></tr><tr><td><i>15-29.9</i></td><td>23 (23.2)</td><td>19 (27.1)</td><td>24 (21.2)</td><td> </td></tr><tr><td><i>≥30</i></td><td>53 (53.5)</td><td>45 (64.3)</td><td>71 (62.8)</td><td> </td></tr></table> |
da78433fd3322fe3e3335de7bb841d0786ad983fb3c78827e0f4ac1161a1365b.png | simple | <table><tr><td>Supernatant conditions</td><td>Protein concentration (mg/mL)</td><td>Degradation (%)</td></tr><tr><td>Culture supernatant</td><td>0.24 ± 0.03</td><td>50.48 ± 2.40</td></tr><tr><td>Super filtered culture supernatant <sup>a</sup></td><td>1.22 ± 0.04</td><td>73.84 ± 1.65</td></tr><tr><td>Boiled culture supernatant</td><td>0.12 ± 0.02</td><td>52.24 ± 1.74</td></tr></table> |
f95ca1498fb99ac14c0635563c95327023f42977fdce7d887fa03b56a3d87b53.png | complex | <table><tr><td rowspan="2" colspan="2"></td><td>Full follow-up scenario</td><td>Early mortality scenario</td></tr><tr><td colspan="2"><i>....Hazard ratio (95 % CI)...</i></td></tr><tr><td rowspan="2">cART</td><td>Yes</td><td>0 · 41 (0 · 18, 0 · 92)</td><td>0 · 28 (0 · 16, 0 · 49)</td></tr><tr><td>No</td><td>1 · 0</td><td>1 · 0</td></tr><tr><td rowspan="2">Cotrimoxazole</td><td>Yes</td><td>0 · 06 (0 · 01, 0 · 26)</td><td>0 · 02 (0 · 01, 0 · 07)</td></tr><tr><td>No</td><td>1 · 0</td><td>1 · 0</td></tr><tr><td rowspan="2">TB cure</td><td>Yes</td><td>0 · 38 (0 · 18, 0 · 84)</td><td>0 · 66 (0 · 38, 01 · 13)</td></tr><tr><td>No</td><td>1 · 0</td><td>1 · 0</td></tr></table> |
be94fe517d2545ede17dcfe9550b53b17f8b9687c2f73055b4833ca5dd2a06bc.png | simple | <table><tr><td>Variables</td><td>AEP monitor group (<i>n</i>= 19)</td><td>RSS monitor group (<i>n</i>= 18)</td><td>P</td></tr><tr><td>Median number of propofol dosage adjustment</td><td>6 [5-7]</td><td>3 [2-3.8]</td><td><0.001</td></tr><tr><td>Time to the first adjustment of the propofol dosage (second)</td><td>137 [117.5-200.5]</td><td>466 [376.5-553.5]</td><td><0.001</td></tr><tr><td>Propofol dosage during examination (μg⋅kg<sup>-1</sup>⋅min<sup>-1</sup>)</td><td>43.5 [28.5-49.3]</td><td>24.2 [15.5-32.4]</td><td>0.025</td></tr><tr><td>Fentanyl dosage during examination (μg⋅kg<sup>-1</sup>⋅hr<sup>-1</sup>)</td><td>2.5 [1.8-3.1]</td><td>2.7 [1.9-3.4]</td><td>0.679</td></tr><tr><td>Percentage of propofol dosage change compared with the baseline dose (%)</td><td>93.5 [48.4-172.3]</td><td>39.5 [30.4-53.9]</td><td>0.011</td></tr><tr><td>Percentage of time at sedation target (%)</td><td>51.3 [47.0-63.5]</td><td>15.4 [9.5-23.5]</td><td><0.001</td></tr><tr><td>Percentage of AAI levels greater than 40 during examination (%)</td><td>35.3 [27.1-51.5]</td><td>84.5 [76.5-90.4]</td><td>0.033</td></tr><tr><td>Patients with significant hypotension (MAP less than 60 mmHg) (%)</td><td>2 (10.5)</td><td>0 (0)</td><td>0.154</td></tr><tr><td>Duration of FB examination (min)</td><td>29 [27-32]</td><td>30 [28-32]</td><td>0.860</td></tr><tr><td>EMG (dB)</td><td>18 [16-23.5]</td><td>20 [17-25]</td><td>0.751</td></tr></table> |
86d69f7f6003d33f7aca5cb1c858f7a268e919a76c310ecb22df73828b9a44d6.png | simple | <table><tr><td>Total (<i>n</i> = 1998)</td><td>ORN/CIT</td><td>PRO/CIT</td><td>ORN/ARG</td><td>Arginine Bioavailability <sup>§</sup></td></tr><tr><td>TG (mg/dL) <sup>φ</sup></td><td>0.062 *</td><td>0.149</td><td>0.027 *</td><td>−0.026</td></tr><tr><td>HDLC (mg/dL) <sup>φ</sup></td><td>−0.051 *</td><td>−0.056</td><td>−0.088 *</td><td>0.110 *</td></tr><tr><td>FBG (mg/dL) <sup>φ</sup></td><td>0.051 *</td><td>0.134</td><td>−0.002 *</td><td>0.021</td></tr><tr><td>SBP (mmHg)</td><td>0.020</td><td>0.038</td><td>0.021</td><td>−0.029</td></tr><tr><td>DBP (mmHg)</td><td>0.041</td><td>0.035 *</td><td>0.054</td><td>−0.051 *</td></tr><tr><td>TC (mg/dL)</td><td>0.010</td><td>0.028 *</td><td>−0.048</td><td>0.074 *</td></tr><tr><td>LDLC (mg/dL)</td><td>−0.017</td><td>−0.022</td><td>−0.043</td><td>0.044</td></tr><tr><td>AST (IU/L) <sup>φ</sup></td><td>0.114 *</td><td>−0.005 *</td><td>0.170</td><td>−0.107 *</td></tr><tr><td>ALT (IU/L) <sup>φ</sup></td><td>0.097 *</td><td>0.079 *</td><td>0.054 *</td><td>−0.025</td></tr></table> |
dd247bc57f8c795756f38da19ec2f80c6223950b50a2095e105356a92a596395.png | simple | <table><tr><td>Background characteristics</td><td>Total %</td></tr><tr><td>Total 85 participants</td><td> </td></tr><tr><td>Age in years</td><td> </td></tr><tr><td>≥20</td><td>7.7</td></tr><tr><td>21-30 yrs</td><td>37.2</td></tr><tr><td>31-40 yrs</td><td>14.1</td></tr><tr><td>41-50 yrs</td><td>9</td></tr><tr><td>≤ 50</td><td>3.8</td></tr><tr><td>Missing data</td><td>28</td></tr><tr><td>Education</td><td> </td></tr><tr><td>Illiterate</td><td>26.9</td></tr><tr><td>1 to 5 yrs</td><td>6.4</td></tr><tr><td>6 to 10 yrs</td><td>35.9</td></tr><tr><td>≤ 12 yrs</td><td>11.6</td></tr><tr><td>Missing data</td><td>19.2</td></tr><tr><td>Place of last birth</td><td> </td></tr><tr><td>No child</td><td>1.3</td></tr><tr><td>Pregnant</td><td>3.8</td></tr><tr><td>Home</td><td>30.8</td></tr><tr><td>Govt</td><td>15.4</td></tr><tr><td>Private</td><td>26.9</td></tr><tr><td>Missing data</td><td>21.8</td></tr><tr><td>Number of children</td><td> </td></tr><tr><td>No child</td><td>7.1</td></tr><tr><td>Pregnant</td><td>9.0</td></tr><tr><td>1 child</td><td>14.1</td></tr><tr><td>2 children</td><td>24.7</td></tr><tr><td>3 to 4 children</td><td>38.5</td></tr><tr><td>more than 4 children</td><td>4.7</td></tr><tr><td>missing data</td><td>1.3</td></tr></table> |
6d6ea4201d4d9ff57d1f4e4fa5c7f738cc0de2e32521a459d1fede5168399e9e.png | complex | <table><tr><td colspan="5">SNP</td><td colspan="3">Gene</td><td colspan="2">SNP vs. IC50</td><td colspan="2">SNP vs. Expression</td><td colspan="2">Expression vs. IC50</td></tr><tr><td> rsID</td><td>Chr</td><td>Position</td><td>Region</td><td>MAF</td><td> Probeset</td><td>Gene symbol</td><td> Chr</td><td>R value</td><td> P value</td><td> R value</td><td> P value</td><td> R value</td><td> P value</td></tr><tr><td>rs2290344</td><td>15</td><td>53407088</td><td>Coding</td><td>0.253</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.339</td><td>1.75E-05</td><td>−0.340</td><td>1.06E-08</td><td>−0.212</td><td>5.31E-03</td></tr><tr><td>rs2290344</td><td>15</td><td>53407088</td><td>Coding</td><td>0.253</td><td>242760_x_at</td><td><i>PIGB</i></td><td>15</td><td>0.339</td><td>1.75E-05</td><td>−0.301</td><td>4.81E-07</td><td>−0.294</td><td>8.98E-05</td></tr><tr><td>rs4774760</td><td>15</td><td>53376504</td><td>5′-upstream</td><td>0.416</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.326</td><td>3.63E-05</td><td>−0.283</td><td>2.48E-06</td><td>−0.212</td><td>5.31E-03</td></tr><tr><td>rs4774760</td><td>15</td><td>53376504</td><td>5′-upstream</td><td>0.416</td><td>242760_x_at</td><td><i>PIGB</i></td><td>15</td><td>0.326</td><td>3.63E-05</td><td>−0.240</td><td>6.85E-05</td><td>−0.294</td><td>8.98E-05</td></tr><tr><td>rs8024695</td><td>15</td><td>53426597</td><td>Intron</td><td>0.285</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.321</td><td>5.00E-05</td><td>−0.326</td><td>4.60E-08</td><td>−0.212</td><td>5.31E-03</td></tr><tr><td>rs8024695</td><td>15</td><td>53426597</td><td>Intron</td><td>0.285</td><td>242760_x_at</td><td><i>PIGB</i></td><td>15</td><td>0.321</td><td>5.00E-05</td><td>−0.282</td><td>2.56E-06</td><td>−0.294</td><td>8.98E-05</td></tr><tr><td>rs12050587</td><td>15</td><td>53414820</td><td>Intron</td><td>0.450</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.305</td><td>1.23E-04</td><td>−0.246</td><td>4.54E-05</td><td>−0.212</td><td>5.31E-03</td></tr><tr><td>rs28668016</td><td>15</td><td>53398725</td><td>5′-UTR</td><td>0.365</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.304</td><td>1.31E-04</td><td>−0.346</td><td>5.97E-09</td><td>−0.212</td><td>5.31E-03</td></tr><tr><td>rs28668016</td><td>15</td><td>53398725</td><td>5′-UTR</td><td>0.365</td><td>242760_x_at</td><td><i>PIGB</i></td><td>15</td><td>0.304</td><td>1.31E-04</td><td>−0.274</td><td>5.28E-06</td><td>−0.294</td><td>8.98E-05</td></tr><tr><td>rs11636687</td><td>15</td><td>53392444</td><td>5′-upstream</td><td>0.421</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.302</td><td>1.53E-04</td><td>−0.287</td><td>2.22E-06</td><td>−0.212</td><td>5.31E-03</td></tr><tr><td>rs7174876</td><td>15</td><td>53406853</td><td>Intron</td><td>0.423</td><td>205452_at</td><td><i>PIGB</i></td><td>15</td><td>0.284</td><td>4.06E-04</td><td>−0.261</td><td>1.64E-05</td><td>−0.212</td><td>5.31E-03</td></tr></table> |
8dc01a8ac6b2e910d71a65335cb5273056db47b126d2ea3be971d832d786c016.png | complex | <table><tr><td>Treatment</td><td colspan="6">Target:Control Ratio</td></tr><tr><td></td><td colspan="3">24 Hour</td><td colspan="3">48 Hour</td></tr><tr><td></td><td>MT1-MMP ± SEM</td><td>MMP-11 ± SEM</td><td>18S rRNA ± SEM</td><td>MT1-MMP ± SEM</td><td>MMP-11 ± SEM</td><td>18S rRNA ± SEM</td></tr><tr><td>Control</td><td>1.00 ± 0.02</td><td>1.00 ± 0.02</td><td>1.00 ± 0.02</td><td>1.00 ± 0.08</td><td>1.00 ± 0.04</td><td>1.00 ± 0.05</td></tr><tr><td>Collagen I</td><td>1.00 ± 0.08</td><td>1.38 ± 0.18</td><td>0.90 ± 0.04</td><td>0.84 ± 0.06</td><td>1.20 ± 0.10</td><td>0.94 ± 0.04</td></tr><tr><td>Collagen IV</td><td>1.10 ± 0.06</td><td>1.65 ± 0.08</td><td>0.58 ± 0.06</td><td>1.00 ± 0.08</td><td>1.45 ± 0.12</td><td>0.60 ± 0.05</td></tr><tr><td>Collagen V</td><td>1.04 ± 0.10</td><td>1.65 ± 0.08</td><td>0.60 ± 0.06</td><td>0.90 ± .004</td><td>1.80 ± 0.10</td><td>0.56 ± 0.02</td></tr><tr><td>Con-A</td><td>1.20 ± 0.14</td><td>0.66 ± 0.12</td><td>0.78 ± 0.08</td><td>0.95 ± 0.08</td><td>0.85 ± 0.10</td><td>0.80 ± 0.04</td></tr><tr><td>TGF-β</td><td>0.90 ± 0.06</td><td>0.56 ± 0.06</td><td>0.60 ± 0.02</td><td>0.84 ± 0.08</td><td>0.75 ± 0.05</td><td>0.64 ± 0.08</td></tr><tr><td>Fibronectin</td><td>1.07 ± 0.12</td><td>0.71 ± 0.08</td><td>0.58 ± 0.02</td><td>0.95 ± 0.32</td><td>0.95 ± 0.07</td><td>0.64 ± 0.04</td></tr><tr><td>IL-1β</td><td>1.34 ± 0.02</td><td>0.65 ± 0.04</td><td>0.55 ± 0.02</td><td>1.45 ± 0.16</td><td>1.86 ± 0.20</td><td>0.55 ± 0.03</td></tr><tr><td>IL-2</td><td>0.88 ± 0.20</td><td>0.66 ± 0.08</td><td>0.50 ± 0.02</td><td>0.96 ± 0.04</td><td>1.50 ± 0.10</td><td>0.56 ± 0.06</td></tr><tr><td>IL-6</td><td>1.03 ± 0.04</td><td>0.72 ± 0.04</td><td>0.65 ± 0.02</td><td>0.75 ± 0.06</td><td>1.15 ± 0.12</td><td>0.60 ± 0.02</td></tr></table> |
3dfc596b5f0998e2d2ba56ab77f1382711614f3baee8bc08e3dffd82afadfff3.png | simple | <table><tr><td>Indicator</td><td>Mean 1</td><td>Mean 2</td><td>SD 1</td><td>SD 2</td><td> </td><td><i>p</i></td><td>Error</td></tr><tr><td>1</td><td>15.38 mm</td><td>15.59 mm</td><td>7.52</td><td>7.51</td><td>−0.94</td><td>0.34</td><td>0.97</td></tr><tr><td>2</td><td>60.95 mm</td><td>60.71 mm</td><td>7.69</td><td>7.75</td><td>1.45</td><td>0.15</td><td>0.76</td></tr><tr><td>3</td><td>15.03°</td><td>15.17°</td><td>4.23</td><td>4.07</td><td>—</td><td>0.19</td><td>0.48</td></tr></table> |
57637f7bcd960abe42622e2dff3b520f12cbf170dfdfee67298007b032abb3f7.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3"> GD</td><td colspan="3"> HT</td></tr><tr><td>Tx (<i>n</i> = 28)</td><td>Ct (<i>n</i> = 16)</td><td><i>P</i> value</td><td>Tx (<i>n</i> = 39)</td><td>Ct (<i>n</i> = 17)</td><td><i>P</i> value</td></tr><tr><td>Age (year)</td><td>36.2 ± 14.19</td><td>37.24 ± 10.26</td><td>0.156</td><td>41.40 ± 13.76</td><td>43.82 ± 12.48</td><td>0.168</td></tr><tr><td>Gender (male/female)</td><td>14/28</td><td>6/16</td><td>0.492</td><td>11/39</td><td>7/17</td><td>0.254</td></tr><tr><td> BMI (kg/m<sup>2</sup>)</td><td>21.11 ± 2.46</td><td>22.94 ± 3.16</td><td>0.061</td><td>23.13 ± 3.57</td><td>22.83 ± 4.01</td><td>0.071</td></tr><tr><td>SBP (mmHg)</td><td>117.87 ± 12.26</td><td>114.55 ± 11.43</td><td>0.112</td><td>120.25 ± 15.24</td><td>114.27 ± 17.64</td><td>0.057</td></tr><tr><td>DBP (mmHg)</td><td>76.47 ± 10.23</td><td>78.58 ± 9.15</td><td>0.135</td><td>86.08 ± 13.44</td><td>77.98 ± 10.21</td><td>0.106</td></tr><tr><td>HR (/min)</td><td>88.53 ± 5.82</td><td>86.89 ± 4.53</td><td>0.171</td><td>75.42 ± 9.32</td><td>78.36 ± 8.34</td><td>0.770</td></tr><tr><td>FT3 (pmol/L)</td><td>9.52 ± 7.53</td><td>8.96 ± 1.43</td><td>0.308</td><td>3.39 ± 1.01</td><td>3.42 ± 1.12</td><td>0.640</td></tr><tr><td>FT4 (pmol/L)</td><td>23.01 ± 17.26</td><td>25.93 ± 10.46</td><td>0.112</td><td>11.83 ± 3.64</td><td>10.47 ± 3.59</td><td>0.318</td></tr><tr><td> TSH (<i>μ</i>IU/L)</td><td>0.07 ± 0.13</td><td>0.09 ± 0.17</td><td>0.451</td><td>10.94 ± 6.52</td><td>9.75 ± 7.21</td><td>0.522</td></tr><tr><td>TPO-Ab (IU/mL)</td><td>659.28 ± 585.89</td><td>672.39 ± 463.51</td><td>0.086</td><td>820.51 ± 372.45</td><td>829.39 ± 388.29</td><td>0.455</td></tr><tr><td>TG-Ab (IU/mL)</td><td>—</td><td>—</td><td>—</td><td>547.8 ± 331.45</td><td>593.28 ± 273.65</td><td>0.383</td></tr><tr><td>TR-Ab (IU/mL)</td><td>34.51 ± 17.97</td><td>31.16 ± 11.46</td><td>0.128</td><td>—</td><td>—</td><td>—</td></tr><tr><td>CD3<sup>+</sup> (%)</td><td>66.98 ± 9.40</td><td>67.62 ± 8.36</td><td>0.196</td><td>69.56 ± 8.57</td><td>67.62 ± 8.36</td><td>0.146</td></tr><tr><td>CD4<sup>+</sup> (%)</td><td>38.30 ± 5.37</td><td>36.96 ± 2.29</td><td>0.227</td><td>34.47 ± 6.74</td><td>33.96 ± 4.29</td><td>0.238</td></tr><tr><td>CD8<sup>+</sup> (%)</td><td>21.93 ± 4.46</td><td>21.98 ± 6.56</td><td>0.348</td><td>29.07 ± 7.06</td><td>28.98 ± 6.54</td><td>0.074</td></tr><tr><td>CD4<sup>+</sup>/CD8<sup>+</sup> ratio</td><td>1.86 ± 0.66</td><td>1.89 ± 0.79</td><td>0.105</td><td>1.23 ± 0.55</td><td>1.19 ± 0.68</td><td>0.089</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.